Certificate of Mailing

Date of Deposit __May 5, 2000__   Label Number: _____EL488650106US_____

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as **"Express Mail Post Office to Addressee"** with sufficient postage on the date indicated above and is addressed to BOX PCT, Assistant Commissioner of Patents, Washington, D.C. 20231.

_____Luis A. Cruz_____

Printed name of person mailing correspondence   Signature of person mailing correspondence

| Substitute Form PTO 1390 U.S. Department of Commerce Patent and Trademark Office TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371	Attorney's Docket Number: 04585/048002 U.S. Application Number: Not known yet

INTERNATIONAL APPLICATION NUMBER	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/US98/21349	08 October 1998	14 October 1997

TITLE OF INVENTION:	THERAPEUTIC METHODS COMPRISING USE OF A NEUREGULIN
APPLICANTS FOR DO/EO/US:	Robert N. McBurney, William Holt, David I. Gwynne, and Mark Marchionni

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1.	X	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2.		This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3.	X	This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4.	X	A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5.	X	A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
a.	X	is transmitted herewith (required only if not transmitted by the International Bureau).
b.		has been transmitted by the International Bureau.
c.		Is not required, as the application was filed with the United States Receiving Office (RO/US).
6.		A translation of the International Application into English (35 U.S.C. 371(c)(2).
7.	X	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
a.		are transmitted herewith (required only if not transmitted by the International Bureau).
b.		have been transmitted by the International Bureau.
c.		have not been made; however, the time limit for making such amendments has NOT expired.
d.	X	have not been made and will not be made.
8.		A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9.	X	An unsigned oath or declaration of the inventors (35 U.S.C. 371(c)(4)).
10.		A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5).

11.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.		
12.		An assignment for recording. A separate cover sheet in compliance with 37 3.28 and 3.31 is included.		
13.	X	A FIRST preliminary amendment.		
		A SECOND or SUBSEQUENT preliminary amendment.		
14.		A substitute specification.		
15.		A change of power of attorney and/or address letter.		
16.		Other items or information:		

17.		The following fees are submitted:		
		BASIC NATIONAL FEE (37 CFR 1.492(A)(1)-(5)):		
		Search Report has been prepared by the EPO or JPO $ 840.00		
		International preliminary examination fee paid to USPTO (37 CFR 1.482) $ 670.00	$670.00	
		No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee (37 CFR 1.445(a)(2)) paid to USPTO $ 690.00		
		Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO $ 970.00		
		International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) $ 96.00		

ENTER APPROPRIATE BASIC FEE AMOUNT =				$670.00	
Surcharge of $130 for furnishing the oath or declaration later than ☐ 20 OR ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				$	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	38 - 20 = 8	8	x $18.00	$144.00	
Independent claims	4 - 3 =	1	x $78.00	$ 78.00	
Multiple dependent claims (if applicable)			+ $260.00	$ 260.00	

TOTAL OF ABOVE CALCULATIONS =			$1,152.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed with this request (Note 37 CFR 1.9, 1.27, 1.28).			$	
SUBTOTAL =			$1,152.00	
Processing fee of $130.00 for furnishing the English translation later than ☐ 20 OR ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +			$	
TOTAL NATIONAL FEE =			$1,152.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). $40.00 per property. +			$	
TOTAL FEES ENCLOSED =			$1,152.00	
			Amount to be refunded	$
			charged	$

\\Ntserver\documents\04585\04585.048WO2 PTO 1390 National Phase Transmittal.wpd   Revised: 17 March 2000

a.	X	A check in the amount of $1,152.00 to cover the above fees is enclosed.
b.		Please charge my Deposit Account No. 03-2095 in the amount of $ [**.**] to cover the above fees.
c.	X	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 03-2095. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.

| SEND ALL CORRESPONDENCE TO: Kristina Bieker-Brady, Ph.D. Clark & Elbing LLP 176 Federal Street Boston, MA 02110-2214 Telephone: 617-428-0200 Facsimile: 617-428-7045	Signature Kristina Bieker-Brady, Ph.D. Reg No. 39,109

\\Ntserver\documents\04585\04585.048WO2 PTO 1390 National Phase Transmittal.wpd

PATENT
ATTORNEY DOCKET NO. 04585/048002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Robert N. McBurney et al.	Art Unit:	Not yet Assigned
Serial No.:	Not yet Assigned	Examiner:	Not yet Assigned
	Based on PCT/US98/21349		
Filed:	08 October 1998		
Title:	THERAPEUTIC METHODS COMPRISING USE OF A NEUREGULIN		

Assistant Commissioner of Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, Applicants submit the following amendment.

In the claims

Cancel claims 7, 9, 12-21, 24-26, and 28-34. Amend claims 8, 10, 11, 22, 23, 27, 35, and 36 as follows.

8. (Once Amended) [A] The method of [claim 7] claims 1, 2, 3, or 4, wherein the neuregulin or fragment or derivative thereof comprises an amino acid sequence of the following formula:

WYBAZCX

wherein WYBAZCX is composed of amino acid sequences that include one or more

sequences shown in FIGS. 1 through 15 (which includes SEQ ID NOS:2, 4, 5, 8, 9, 12,

14, 15, 18, 19, 22, 23, 26, 27, 30, 33, 35, 38, 39, 41, 44, 45 and 48), wherein W comprises

the polypeptide segment F, or is absent; wherein Y comprises the polypeptide segment E,

or is absent; wherein Z comprises the polypeptide segment G or is absent; and wherein X

comprise a polypeptide segment selected from the group consisting of C/D HKL, C/D H,

C/D HL, C/D D, C/D' HL, C/D' HKL, C/D' H, C/D' D, C/D C/D' HKL, C/D C/D' H, C/D

C/D' HL, C/D C/D' D, C/d D'H, C/D D' HL, C/D D' HKL, C/D' D' H, C/D' D' HL, C/D' D'

HKL, C/D C/D' D' H, C/D C/D' D' HL and C/D C/D' D' HKL, and preferably that either

    a)   at least one of F, Y, B, A, Z, C or X is of bovine origin; or

    b)   Y comprises the polypeptide segment E; or

    c)   X comprises the polypeptide segments C/D HKL, C/D D, C/D' HKL, C/D

C/D' HKL, C/D C/D' D, C/D D' H, C/D D' HL, C/D D' HKL, C/D' D' H, C/D' D' HKL,

C/D C/D' D'H, C/D C/D' D HL, C/D C/D' D' HKL, C/D'H, C/D C/D' H or C/D C/D' HL.

10. (Once Amended) The method of [claim 7] claims 1, 2, 3, or 4, wherein the

neuregulin or fragment or derivative thereof comprises FBA polypeptide segments,

FEBA polypeptides segments, EBA polypeptide segments, EBA' polypeptide segments or

FEBA' polypeptide segments.

11. (Once Amended) The method of [claim 7] claims 1, 2, 3, or 4, wherein the

- 2 -

neuregulin is encoded by a nucleic acid that [comprises one of] is selected from the group consisting of SEQ ID NOS: 49, 51 and 53.

22. (Once Amended) The method of [claim 7] claims 1, 2, 3, or 4, wherein the neuregulin or fragment or derivative comprises a sequence that is shown in Figures 7, 8 or 9.

23. (Once Amended) [A] The method of any one of claims [1-6] 1-4, wherein a nucleic acid encoding a neuregulin or a fragment or derivative thereof is administered to the mammal.

27. (Once Amended) The method of [claim 25] claims 1, 2, 3, or 4, wherein the neuregulin or neuregulin fragment or derivative comprises FBA polypeptide segments, FEBA polypeptides segments, EBA polypeptide segments, EBA' polypeptide segments or FEBA' polypeptide segments.

35. (Once Amended) [A] The method of any one of claims [1-34] 1-4, wherein the administered neuregulin or fragment or derivative[, or the administered nucleic acid encodes a neuregulin fragment or derivative] exhibits at least about a 10% reduction in infarct volume in an *in vivo* cerebral ischemia assay.

36. (Once Amended) [A] The method of any one of claims [1-34] 1-4, wherein the mammal is a human.

REMARKS

No new matter has been introduced by the above amendments. If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: May 5, 2000

Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

\\Ntserver\documents\04585\04585.048002 Preliminary Amendment.wpd

- 1 -

THERAPEUTIC METHODS COMPRISING USE OF A NEUREGULIN

BACKGROUND OF THE INVENTION

1.   Field of the Invention

The present invention relates to methods for treatment of certain neurological-related injuries and disorders comprising use of a neuregulin, or a fragment or

5   derivative of a neuregulin, or a nucleic acid encoding a neuregulin or neuregulin fragment or derivative.

2.   Background

Nerve cell death (degeneration) can cause potentially devastating and irreversible effects for an individual and may occur e.g. as a result of stroke, heart

10   attack or other brain or spinal chord ischemia or trauma. Additionally, neurodegenerative disorders involve nerve cell death (degeneration) such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Down's Syndrome and Korsakoff's disease.

Therapies have been investigated to treat nerve cell degeneration and related

15   disorders, e.g., by limiting the extent of nerve cell death that may otherwise occur to an individual as well as promoting repair, remodeling and reprogramming after stroke or other neuronal injury. See, e.g., F. Seil, *Curr Opin Neuro*, 10:49-51 (1997); N. L. Reddy et al., *J Med Chem*, 37:260-267 (1994); and WO 95/20950.

Certain growth factors have been reported to exhibit neuroprotective

20   properties. In particular, nerve growth factor (NGF) has been evaluated in certain neuroprotective models. See, for example, G. Sinson et al., *J Neurosurg*, 86(3):511-518 (1997); and G. Sinson et al., *J Neurochem*, 65(5):2209-2216 (1995). Osteogenic protein-1 (OP-1) has been evaluated in a rat model of cerebral hypoxia/ischemia for neuroprotective activity. G. Perides, *Neurosci Lett*, 1871):21-24 (1995). Glial cell

25   line-derived neurotrophic factor (GDNF) was reported to exhibit trophic activity on certain populations of central neurons. Y. Wang et al., *J Neurosci*, 17(11):4341-4348 (1997). Small molecules also have been investigated as neuroprotective agents, such

- 2 -

as MK-801. See B. Meldrum , *Cereb Brain Metab Rev*, 2:27-57 (1990); D. Choi, *Cereb Brain Metab Rev*, 2:27-57 (1990).

However, no effective pharmacotherapies are in regular clinical use for ischemia-induced brain injury or other such injuries and disorders. See, for example, 5 Y. Wang et al., *supra*; G. Sinson et al., *J Neurochem, J Neurochem*, 65(5):2209 (1995).

It thus would be highly desirable to have new neuroprotective agents, particularly agents to limit the extent or otherwise treat nerve cell death (degeneration) that occur with stroke, heart attack or brain or spinal cord trauma, or to treat 10 Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Down's Syndrome and Korsakoff's disease. It also would be desirable to have agents that promote repair, remodeling or reprogramming after stroke or other neuronal injury.

SUMMARY OF THE INVENTION

15 The present invention provides methods for treatment and/or prophylaxis of certain neurological-related disorders, particularly treatment or prophylaxis of the effects of stroke, brain or spinal cord injury or ischemia, heart attack, optic nerve and retinal injury and ischemia and other acute-type conditions disclosed herein as well as chronic-type conditions, specifically epilepsy, Alzheimer's disease, Parkinson's 20 disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Down's Syndrome, Korsakoff's disease, cerebral palsy and/or age-dependent dementia. Methods of the invention also include therapies for promoting repair, remodeling or reprogramming after stroke or other neuronal injury.

The methods of the invention comprise administration of an effective amount 25 of neuregulin, or fragment or derivative of a neuregulin, or a nucleic acid encoding a neuregulin or a neuregulin fragment or derivative (i.e. gene therapy), to a patient suffering from or susceptible to such conditions.

Neuregulins are members of the epidermal growth factor (EGF) superfamily and include glial growth factor (GGF), acetylcholine receptor-inducing activity 30 (ARIA), neu differentiation factor (NDF) and heregulins (HRF). See D. E. Wen et al., *Cell*, 69:559-572 (1992); W.E. Holmes et al., *Science*, 256:1205-1210 (1992); M.A. Marchionni et al., *Nature*, 362:312-318 (1993); and D.L. Falls, *Cell*, 72:801-815

- 3 -

(1993). A variety of neuregulins and fragments and derivatives thereof can be employed in the methods of the invention. For example, suitable agents have been disclosed in U.S. Patent 5,530,109 and PCT/US93/07491. Neuregulins also have been reported in U.S. Patent 5,367,060. Preferred neuregulins include regions shown

5   in FIGS. 1-2 (SEQ ID NOS. 2 and 4), also known as the E sequence. Preferred neuregulins or fragments or derivatives also include those that contain the C, C/D or C/D' sequences as shown in Figures 7, 8 and 9 respectively of the drawings, or those neuregulins or fragments or derivatives that have substantial homology to the peptide sequences shown in Figures 7, 8 or 9, e.g. at least about 70 percent homology, or at

10   least about 80 percent homology, or more preferably at least about 90 or 95 percent homology to the peptide sequences shown in Figures 7, 8 or 9. Preferred nucleic acids and fragments and derivatives for use in the methods of the invention include those nucleic acids that include one or more nucleic acids sequences shown in Figures 7, 8 and 9 of the drawings, or those nucleic acids that that have substantial homology

15   to the nucleic acid sequences shown in Figures 7, 8 or 9, e.g. at least about 70, 80, 90 or 95 percent homology to the nucleic acid sequences shown in Figures 7, 8 or 9. A particularly preferred neuregulin is encoded by DNA obtainable from the clone pGGF2HBS11 (ATCC Deposit No. 75347). Also preferred are neuregulins encoded by DNA obtainable from GGF2BPP5, GGF2BPP2 and GGF2BPP4.

20   Typical patients that may be treated in accordance with the methods of the invention are persons suffering from brain or spinal cord trauma or ischemia, stroke, heart attack, hypoxia, hypoglycemia, post-surgical neurological deficits, decreased blood flow or nutrient supply to retinal tissue or optic nerve, retinal trauma or ischemia or optic nerve injury. Patients suffering from chronic-type conditions also

25   may be treated in accordance with the invention, specifically subjects suffering from or susceptible to epilepsy, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Alzheimer's disease, Down's Syndrome, Korsakoff's disease, cerebral palsy and/or age-dependent dementia.

       Also, as discussed above, a neuregulin or fragment or derivative thereof or

30   nucleic acid encoding same, may be administered to promote repair, remodeling or reprogramming to a subject that has suffered stroke or other neuronal injury such as traumatic brain or spinal cord injury. In such cases, the therapeutic agent may be

- 4 -

suitably administered to the subject over an extended period following the injury, e.g. at least about 1, 2, 3, 4, 6, 8, 12 or 16 weeks following the injury.

Other aspects of the invention are disclosed *infra*.

BRIEF DESCRIPTION OF THE DRAWINGS

5   FIG. 1 shows a nucleotide sequence (SEQ ID NO:1) encoding a preferred neuregulin region (E segment of human GGF) and the amino acid sequence (SEQ ID NO:2) of that preferred region.

FIG. 2 shows a nucleotide sequence (SEQ ID NO:3) encoding a preferred neuregulin region (E segment of bovine GGF) and the amino acid sequence (SEQ ID

10   NO:4) of that preferred region.

FIG. 3 shows nucleotide sequences (SEQ ID NOS:6-7) encoding further neuregulin regions (B segment of human and bovine GGF) and amino acid sequences (SEQ ID NOS:5 and 8) of those regions. Line 1 is the predicted amino acid sequence of bovine B segment, line 2 is a nucleotide sequence of bovine B segment, line 3 is a

15   nucleotide sequence of human B segment (nucleotide base matches are indicated with a vertical line), and line 4 is the predicted amino acid sequence of human B segment shown where it differs from the bovine sequence set forth in line 1 of the figure.

FIG. 4 shows nucleotide sequences (SEQ ID NOS:10-11) encoding further neuregulin regions (A segment of human and bovine GGF) and amino acid sequences

20   (SEQ ID NOS:9 and 12) of those regions. Line 1 is the predicted amino acid sequence of bovine A segment, line 2 is a nucleotide sequence of bovine A segment, line 3 is a nucleotide sequence of human A segment (nucleotide base matches are indicated with a vertical line), and line 4 is the predicted amino acid sequence of human A segment shown where it differs from the bovine sequence set forth in line 1

25   of the figure.

FIG. 5 shows a nucleotide sequence (SEQ ID NO:13) encoding a further neuregulin region (A' segment of bovine GGF) and the predicted amino acid sequence (SEQ ID NO:14) of that region.

FIG. 6 shows nucleotide sequences (SEQ ID NOS:16-17) encoding further

30   neuregulin regions (G segment of bovine and human GGF) and amino acid sequences (SEQ ID NOS:15 and 18) of that region. Line 1 is the predicted amino acid sequence of bovine G segment, line 2 is a nucleotide sequence of bovine G segment, line 3 is a

- 5 -

nucleotide sequence of human G segment (nucleotide base matches are indicated with a vertical line), and line 4 is the predicted amino acid sequence of human G segment shown where it differs from the bovine sequence set forth in line 1 of the figure.

FIG. 7 shows nucleotide sequences (SEQ ID NOS:20-21) encoding further neuregulin regions (C segment of bovine and human GGF) and amino acid sequences (SEQ ID NOS:19 and 22) of those regions. Line 1 is the predicted amino acid sequence of bovine C segment, line 2 is a nucleotide sequence of bovine C segment, line 3 is a nucleotide sequence of human C segment (nucleotide base matches are indicated with a vertical line), and line 4 is the predicted amino acid sequence of human C segment shown where it differs from the bovine sequence set forth in line 1 of the figure.

FIG. 8 shows nucleotide sequences (SEQ ID NOS:24-25) encoding further neuregulin regions (C/D segment of human and bovine GGF) and amino acid sequences (SEQ ID NOS:23 and 26) of those regions. Line 1 is the predicted amino acid sequence of bovine C/D segment, line 2 is a nucleotide sequence of bovine C/D segment, line 3 is a nucleotide sequence of human C/D segment (nucleotide base matches are indicated with a vertical line), and line 4 is the predicted amino acid sequence of human C/D segment shown where it differs from the bovine sequence set forth in line 1 of the figure.

FIG. 9 shows nucleotide sequences (SEQ ID NOS:28-29) encoding a further neuregulin region (C/D' segment of the human and bovine GGF) and the amino acid sequence (SEQ ID NO:27) of that region. Line 1 is the predicted amino acid sequence of the C/D' segment, line 2 is a nucleotide sequence of bovine C/D' segment and line 3 is a nucleotide sequence of human C/D' segment (nucleotide base matches are indicated with a vertical line).

FIG. 10 shows nucleotide sequences (SEQ ID NOS:31-32) encoding a further neuregulin region (D segment of the human and bovine GGF) and the amino acid sequence (SEQ ID NO:30) of that region. Line 1 is the predicted amino acid sequence of the D segment, line 2 is a nucleotide sequence of bovine D segment and line 3 is a nucleotide sequence of human D segment (nucleotide base matches are indicated with a vertical line).

- 6 -

FIG. 11 shows nucleotide sequence (SEQ ID NO:34) encoding a further neuregulin region (D' segment of bovine GGF) and the amino acid sequence (SEQ ID NO:33) of that region.

FIGS. 12A-12B show nucleotide sequences (SEQ ID NOS:36-37) encoding

5   further neuregulin regions (H segment of human and bovine GGF) and amino acid sequences (SEQ ID NO:35 and 38) of that region. Line 1 is the predicted amino acid sequence of bovine H segment, line 2 is a nucleotide sequence of bovine H segment, line 3 is a nucleotide sequence of human H segment (nucleotide base matches are indicated with a vertical line), and line 4 is the predicted amino acid sequence of

10   human H segment shown where it differs from the bovine sequence set forth in line 1 of the figure.

FIG. 13 shows a nucleotide sequence (SEQ ID NO:40) encoding a further neuregulin region (K segment of bovine GGF) and the amino acid sequence (SEQ ID NO:39) of that region.

15   FIGS. 14A-14C show nucleotide sequences (SEQ ID NOS:42-43) encoding a further neuregulin region (L segment of bovine and human GGF) and amino acid sequences (SEQ ID NO:41 and 44) of that region. Line 1 is the predicted amino acid sequence of bovine L segment, line 2 is a nucleotide sequence of bovine L segment, line 3 is a nucleotide sequence of human L segment (nucleotide base matches are

20   indicated with a vertical line), and line 4 is the predicted amino acid sequence of human L segment shown where it differs from the bovine sequence set forth in line 1 of the figure.

FIG. 15 shows nucleotide sequences (SEQ ID NOS:46-47) encoding further neuregulin regions (F segment of bovine and human GGF) and amino acid sequences

25   (SEQ ID NOS:45 and 48) of that region. Line 1 is the predicted amino acid sequence of bovine F segment, line 2 is a nucleotide sequence of bovine F segment, line 3 is a nucleotide sequence of human F segment (nucleotide base matches are indicated with a vertical line), and line 4 is the predicted amino acid sequence of human F segment shown where it differs from the bovine sequence set forth in line 1 of the figure.

30   FIGS. 16A-16C show the nucleotide sequence (SEQ ID NO:49) and deduced amino acid sequence (SEQ ID NO:50) of GGF2BPP4.

- 7 -

FIGS. 17A-17B show the nucleotide sequence (SEQ ID NO:51) and deduced amino acid sequence (SEQ ID NO:52) of GGF2BPP2.

FIGS. 18A-18B show the nucleotide sequence (SEQ ID NO:53) and deduced amino acid sequence (SEQ ID NO:54) of GGF2BPP5.

5   DETAILED DESCRIPTION OF THE INVENTION

As discussed above, preferred neuregulins for use in the therapeutic methods of the present invention include those disclosed in U.S. Patent 5,530,109 and PCT/US93/07491, incorporated herein by reference. Particularly preferred neuregulins comprise an amino acid sequence of the following formula:

10   WYBAZCX

wherein WYBAZCX is composed of amino acid sequences that include one or more sequences shown in FIGS. 1 through 15 (which includes SEQ ID NOS:2, 4, 5, 8, 9, 12, 14, 15, 18, 19, 22, 23, 26, 27, 30, 33, 35, 38, 39, 41, 44, 45 and 48), wherein W comprises the polypeptide segment F, or is absent; wherein Y comprises the

15   polypeptide segment E, or is absent; wherein Z comprises the polypeptide segment G or is absent; and wherein X comprise a polypeptide segment selected from the group consisting of C/D HKL, C/D H, C/D HL, C/D D, C/D' HL, C/D' HKL, C/D' H, C/D' D, C/D C/D' HKL, C/D C/D' H, C/D C/D' HL, C/D C/D' D, C/d D'H, C/D D' HL, C/D D' HKL, C/D' D' H, C/D' D' HL, C/D' D' HKL, C/D C/D' D' H, C/D C/D' D'

20   HL and C/D C/D' D' HKL, and preferably that either

          a)   at least one of F, Y, B, A, Z, C or X is of bovine origin; or

          b)   Y comprises the polypeptide segment E; or

          c)   X comprises the polypeptide segments C/D HKL, C/D D, C/D' HKL, C/D C/D' HKL, C/D C/D' D, C/D D' H, C/D D' HL, C/D D' HKL, C/D' D' H, C/D'

25   D' HKL, C/D C/D' D'H, C/D C/D' D HL, C/D C/D' D' HKL, C/D'H, C/D C/D' H or C/D C/D' HL.

Particularly preferred neuregulins also include those polypeptides that include the segments FB polypeptides that include the segments FBA' (i.e. the groups F, B and A' as defined herein including in the drawings); polypeptides that include the

30   segments EBA (i.e. the groups E, B and A as defined herein including in the drawings); polypeptides that include the segments EBA' (i.e. the groups E, B and A' as defined herein including in the drawings); A (i.e. the group A as defined herein

- 8 -

including in the drawings); polypeptides that include the segments FEBA (i.e. the groups F, E, B and A as defined herein including in the drawings); polypeptides that include the segments FBA' (i.e. the groups F, B and A' as defined herein including in the drawings); and polypeptides that include the segments FEBA' (i.e. the groups F,

5   E, B and A' as defined herein including in the drawings).

Also preferred are nucleic acids that code for the above preferred polypeptides.

A "fragment" or "derivative" of a neuregulin refers to herein 1) a peptide in which one or more amino acid residues are with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino

10   acid residue may or may not be one encoded by the genetic code, or (ii) a peptide in which one or more of the amino acid residues includes a substituent group, or (iii) a peptide in which the mature protein is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol). Thus, a fragment or derivative for use in accordance with the methods of the

15   invention includes a proprotein, which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide.

The polypeptide fragments and derivatives of the invention are of a sufficient length to uniquely identify a region of a neuregulin. Neuregulin fragments thus preferably comprise at least 8 amino acids, usually at least about 12 amino acids, more

20   usually at least about 15 amino acids, still more typically at least about 30 amino acids, even more typically at least about 50 or 70 amino acids. Preferred fragments or derivatives for use in the methods of the invention include those that have at least about 70 percent homology (sequence identity) to any of the preferred sequences mentioned above, more preferably about 80 percent or more homology to any of the

25   preferred sequences mentioned above, still more preferably about 85 to 90 percent or more homology to any of the preferred sequences mentioned above. Sequence identity or homology with respect to a neuregulin as referred to herein is the percentage of amino acid sequences of a neuregulin protein or fragment or derivative thereof that are identical with a specified sequence, after introducing any gaps

30   necessary to achieve the maximum percent homology.

The neuregulin fragments and derivatives for use in the methods of the invention preferably exhibit good activity in standard neuroprotective assays such as

- 9 -

the *in vivo* cerebral ischemia assay of Example 1, which follows. That assay includes the following steps: a) continuous intraventricular infusion of the protein fragment or derivative or vehicle alone to test rats for three days prior to inducing focal ischemic infarcts in right lateral cerebral cortex; and b) twenty-four hours after inducing

5   ischemic infarcts, infarct volume in each test animal is determined by image analysis. Preferably, a protein fragment or derivative of the invention provides at least about a 10% reduction in infarct volume relative to vehicle-treated animals, more preferably about a 20% reduction in infarct volume, still more preferably about a 25% reduction in infarct volume relative to vehicle-treated animals in such an assay. References

10   herein to *in vivo* cerebral ischemia assay are intended to refer to an assay of the above steps a) and b), which are more fully described in Example 1 which follows.

As discussed above, neuregulin nucleic acid fragments and derivatives are also provided for use in the methods of the invention. Those fragments and derivatives typically are of a length sufficient to bind to a sequence of any of the nucleic acid

15   sequences shown in Figures 1-15 of the drawings, including SEQ ID NOS:1, 3, 6, 7, 10, 11, 13, 16, 17, 20, 21, 24, 25, 28, 29, 31, 32, 34, 36, 37, 40, 42 and 43 under the following moderately stringent conditions (referred to herein as "normal stringency" conditions): use of a hybridization buffer comprising 20% formamide in 0.8M saline/0.08M sodium citrate (SSC) buffer at a temperature of 37°C and *remaining*

20   bound when subject to washing once with that SSC buffer at 37°C.

Preferred neuregulin nucleic acid fragments and derivatives of the invention will bind to a sequence of any of the nucleic acid sequences shown in Figures 1-15 of the drawings, including SEQ ID NOS:1, 3, 6, 7, 10, 11, 13, 16, 17, 20, 21, 24, 25, 28, 29, 31, 32, 34, 36, 37, 40, 42 and 43 under the following highly stringent conditions

25   (referred to herein as "high stringency" conditions): use of a hybridization buffer comprising 20% formamide in 0.9M saline/0.09M sodium citrate (SSC) buffer at a temperature of 42°C and remaining bound when subject to washing twice with that SSC buffer at 42°C.

The neuregulin nucleic acid fragments and derivatives preferably should

30   comprise at least 20 base pairs, more preferably at least about 50 base pairs, and still more preferably a nucleic acid fragment or derivative of the invention comprises at least about 100, 200, 300 or 400 base pairs. In some preferred embodiments, the

nucleic acid fragment or derivative is bound to some moiety which permits ready identification such as a radionucleotide, fluorescent or other chemical identifier.

Isolated neuregulin and peptide fragments or derivatives of the invention are preferably produced by recombinant methods, although suitable neuregulins also can

5   be isolated from various sources. See the procedures disclosed U.S. Patent 5,530,109; U.S. Patent 5,367,060; and PCT/US93/07491, incorporated herein by reference. A wide variety of molecular and biochemical methods are available for generating and expressing neuregulin; see e.g. the procedures disclosed in *Molecular Cloning, A Laboratory Manual* (2nd Ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor),

10   *Current Protocols in Molecular Biology* (Eds. Aufubel, Brent, Kingston, More, Feidman, Smith and Stuhl, Greene Publ. Assoc., Wiley-Interscience, NY, N.Y. 1992) or other procedures that are otherwise known in the art. For example, neuregulin or fragments or derivatives thereof may be obtained by chemical synthesis, or more preferably by expression in bacteria such as *E coli* and eukaryotes such as yeast,

15   baculovirus, or mammalian cell-based expression systems, etc., depending on the size, nature and quantity of neuregulin or fragment or derivative thereof. More particularly, a recombinant DNA molecule comprising a vector and a DNA segment encoding neuregulin, or a fragment or derivative thereof, can be constructed. Suitable vectors include e.g. baculovirus-derived vectors for expression in insect cells (see

20   Pennock et al., Mol. Cell. Biol., 4:399-406 (1984)), T7-based expression vector for expression in bacteria (see Rosenberg et al., Gene, 56:125-135 (1987)) and the pMSXND expression vector for expression in mammalian cells (Lee and Nathans, J. Biol. Chem., 263:3521-3527 (1988)). The DNA segment can be present in the vector operably linked to regulatory elements, e.g., a promoter (e.g., polyhedron, T7 or

25   metallothionein (Mt-I) promoters), or a leader sequence to provide for secretory expression of the polypeptide. The recombinant DNA molecule containing the DNA coding for a neuregulin or a fragment or derivative thereof can be introduced into appropriate host cells by known methods. Suitable host cells include e.g. prokaryotes such as E. coli, Bacillus subtilus, etc., and eukaryote such as animal cells and yeast

30   strains, e.g., S. cerevisiae. Mammalian cells may be preferred such as J558, NSO, SP2-O or CHO. In general, conventional culturing conditions can be employed. See Sambrook, *supra*. Stable transformed or transfected cell lines can then be selected.

- 11 -

The expressed neuregulin or fragment or derivative thereof then can be isolated and
purified by known methods. Typically the culture medium is centrifuged and the
supernatant purified by affinity or immunoaffinity chromatography, e.g. Protein-A or
Protein-G affinity chromatography or an immunoaffinity protocol comprising use of
5　　monoclonal antibodies that bind neuregulins.

Neuregulin nucleic acids used in the methods of the invention are typically
isolated, meaning the nucleic acids comprise a sequence joined to a nucleotide other
than that which it is joined to on a natural chromosome and usually constitute at least
about 0.5%, preferably at least about 2%, and more preferably at least about 5% by
10　　weight of total nucleic acid present in a given fraction. A partially pure nucleic acid
constitutes at least about 10%, preferably at least about 30%, and more preferably at
least about 60% by weight of total nucleic acid present in a given fraction. A pure
nucleic acid constitutes at least about 80%, preferably at least about 90%, and more
preferably at least about 95% by weight of total nucleic acid present in a given
15　　fraction.

As discussed above, the present invention includes methods for treating and
preventing certain neurological-related injuries and disorders, comprising the
administration of an effective amount of a neuregulin or fragment or derivative
thereof, or nucleic acid encoding same, to a subject including a mammal, particularly
20　　a human, in need of such treatment.

In particular, the invention provides methods for treatment and/or prophylaxis
of nerve cell death (degeneration) resulting from hypoxia, hypoglycemia, brain or
spinal cord ischemia, brain or spinal cord trauma, stroke, heart attack or drowning.
Typical candidates for treatment include e.g. heart attack, stroke and/or persons
25　　suffering from cardiac arrest neurological deficits, brain or spinal cord injury patients,
patients undergoing major surgery such as heart surgery where brain ischemia is a
potential complication and patients such as divers suffering from decompression
sickness due to gas emboli in the blood stream. Candidates for treatment also will
include those patients undergoing a surgical procedure involving extra-corporal
30　　circulation such as e.g. a bypass procedure.

The invention also provides methods for treatment which comprise
administration of a neuregulin or fragment or derivative thereof, or nucleic acid

- 12 -

encoding same, to a patient that is undergoing surgery or other procedure where brain or spinal cord ischemia is a potential risk. For example, carotid endarterectomy is a surgical procedure employed to correct atherosclerosis of the carotid arteries. Major risks associated with the procedure include intraoperative embolization and the danger

5   of hypertension in the brain following increased cerebral blood flow, which may result in aneurysm or hemorrhage. Thus, an effective amount of a neuregulin or fragment or derivative thereof, or nucleic acid encoding same, could be administered pre-operatively or peri-operatively to reduce such risks associated with carotid endarterectomy, or other post-surgical neurological deficits.

10   The invention also is effective to promote and enhance recovery from acute nerve cell death and neurological conditions. Thus, for example, a neuregulin or fragment or derivative thereof, or nucleic acid encoding same, could be administered to promote repair, remodeling or reprogramming to a patient that has suffered from stroke or other neuronal injury, suitably for an extended period as discussed above. A

15   therapeutic agent of the invention also could be administered post-operatively to promote recovery from any neurological deficits that may have occurred to a patient that has undergone surgery.

The invention further includes methods for prophylaxis against neurological deficits resulting from e.g. coronary artery bypass graft surgery and aortic valve

20   replacement surgery, or other procedure involving extra-corporal circulation. Those methods will comprise administering to a patient undergoing such surgical procedures an effective amount of a neuregulin or fragment or derivative thereof, or nucleic acid encoding same, typically either pre-operatively or peri-operatively.

The invention also provides methods for prophylaxis and treatment against

25   neurological injury for patients undergoing myocardial infarction, a procedure that can result in ischemic insult to the patient. Such methods will comprise administering to a patient undergoing such surgical procedure an effective amount of a neuregulin or fragment or derivative thereof, or nucleic acid encoding same, typically either pre-operatively or peri-operatively.

30   Also provided are methods for treating or preventing neuropathic pain such as may be experienced by cancer patients, persons having diabetes, amputees and other persons who may experience neuropathic pain. These methods for treatment comprise

- 13 -

administration of an effective amount of a neuregulin or fragment or derivative thereof, or nucleic acid encoding same, to a patient in need of such treatment.

The invention also provides methods for treatment and prophylaxis against retinal ischemia or degeneration and resulting visual loss. For example, a neuregulin

5 or fragment or derivative thereof, can be administered parenterally or by other procedure as described herein to a subject a suffering from or susceptible to ischemic insult that may adversely affect retinal function, e.g., significantly elevated intraocular pressures, diseases such as retinal artery or vein occlusion, diabetes or other ischemic ocular-related diseases. Post-ischemic administration also may limit retinal damage.

10 The invention also includes methods for treating and prophylaxis against decreased blood flow or nutrient supply to retinal tissue or optic nerve, or treatment or prophylaxis against retinal trauma or optic nerve injury. Subjects for treatment according to such therapeutic methods of the invention may be suffering or susceptible to retinal ischemia that is associated with atherosclerosis, venous capillary

15 insufficiency, obstructive arterial or venous retinopathies, senile macular degeneration, cystoid macular edema or glaucoma, or the retinal ischemia may be associated with a tumor or injury to the mammal. Intravitreal injection also may be a preferred administration route to provide more direct treatment to the ischemic retina.

The invention further provides a method of treating Korsakoff's disease, a

20 chronic alcoholism-induced condition, comprising administering to a subject including a mammal, particularly a human, an effective amount of a neuregulin or fragment or derivative thereof, in an amount effective to treat the disease. Compounds of the invention are anticipated to have utility for the attenuation of cell loss, hemorrhages and/or amino acid changes associated with Korsakoff's disease.

25 The invention further includes methods for treating a person suffering from or susceptible to epilepsy, emesis, narcotic withdrawal symptoms and age-dependent dementia, comprising administering to a subject including a mammal, particularly a human, an effective amount of a neuregulin or fragment or derivative thereof, in an amount effective to treat the condition.

30 It will be appreciated that in some instances a neuregulin or a fragment or derivative thereof will be preferably administered to a subject rather than a neuregulin nucleic acid, particularly where a patient is suffering from or susceptible to an acute

- 14 -

neurological injury that demands immediate therapy. For example, administration of a neuregulin polypeptide may be preferred to a patient suffering from stroke, heart attack, traumatic brain injury and the like where it is desired to deliver the active therapeutic as quickly as possible.

5　　　　　In the therapeutic methods of the invention, neuregulin peptides and nucleic acids may be suitably administered to a subject such as a mammal, particularly a human, by any of a number of routes including parenteral (including subcutaneous, intramuscular, intravenous and intradermal), oral, rectal, nasal, vaginal and optical (including buccal and sublingual) administration. A neuregulin protein or nucleic acid

10　　or fragment or derivative thereof may be administered to a subject alone or as part of a pharmaceutical composition, comprising the peptide or nucleic acid together with one or more acceptable carriers and optionally other therapeutic ingredients. The carriers should be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

15　　　　　Nucleic acids encoding a neuregulin or a neuregulin fragment or derivative can be administered to a patient by generally known gene therapy procedures. See, for example, WO 90/11092 and WO 93/00051. Thus, for instance, the nucleic acids may be introduced into target cells by any method which will result in the uptake and expression of the nucleic acid by the target cells. These methods can include vectors,

20　　liposomes, naked DNA, adjuvant-assisted DNA, catheters, etc. Preferably, the administered nucleic acid codes for an appropriate secretory sequence to promote expression upon administration. Suitable vectors for administering a nucleic acid in accordance with the invention include chemical conjugates such as described in WO 93/04701, which has targeting moiety (e.g. a ligand to a cellular surface receptor), and

25　　a nucleic acid binding moiety (e.g. polylysine), viral vector (e.g. a DNA or RNA viral vector), fusion proteins such as described in PCT/US 95/02140 (WO 95/22618) which is a fusion protein containing a target moiety (e.g. an antibody specific for a target cell) and a nucleic acid binding moiety (e.g. a protamine), plasmids, phage, etc. The vectors can be chromosomal, non-chromosomal or synthetic.

30　　　　　Preferred vectors include viral vectors, fusion proteins and chemical conjugates. Retroviral vectors include moloney murine leukemia viruses. DNA viral vectors are preferred. These vectors include pox vectors such as orthopox or avipox

- 15 -

vectors, herpes virus vectors such as a herpes simplex I virus (HSV) vector [A.I.

Geller et al., *J. Neurochem*, 64:487 (1995); F. Lim et al., in *DNA Cloning:*

Mammalian Systems, D. Glover, Ed. (Oxford Univ. Press, Oxford England) (1995);

A.I. Geller et al., *Proc Natl. Acad. Sci.* U.S.A.:90 7603 (1993); A.I. Geller et al., *Proc*

5   *Natl. Acad. Sci USA*, 87:1149 (1990)], Adenovirus Vectors [LeGal LaSalle et al.,

Science, 259:988 (1993); Davidson, et al., Nat. Genet., 3:219 (1993); Yang et al., *J.*

Virol., 69:2004 (1995)] and Adeno-associated Virus Vectors [Kaplitt, M.G., et al.,

Nat. Genet., 8:148 (1994)].

Pox viral vectors introduce the gene into the cell cytoplasm. Avipox virus

10   vectors result in only a short-term expression of the nucleic acid. Adenovirus vectors,

adeno-associated virus vectors and herpes simplex virus (HSV) vectors are preferred

for introducing the nucleic acid into neural cells. The adenovirus vector results in a

shorter term expression (about 2 months) than adeno-associated virus (about 4

months), which in turn is shorter than HSV vectors. The particular vector chosen will

15   depend upon the target cell and the specific condition being treated. The introduction

can be by standard techniques, e.g. infection, transfection, transduction or

transformation. Examples of modes of gene transfer include e.g., naked DNA,

$Ca_3(PO_4)_2$ precipitation, DEAE dextran, electroporation, protoplast fusion, lipofecton,

cell microinjection, and viral vectors.

20   A vector can be employed to target essentially any desired target cell. For

example, stereotaxic injection can be used to direct the vectors (e.g. adenovirus, HSV)

to a desired location. Additionally, the particles can be delivered by

intracerebroventricular (icv) infusion using a minipump infusion system, such as a

SynchroMed Infusion System. A method based on bulk flow, termed convection, has

25   also proven effective at delivering large molecules to extended areas of the brain and

may be useful in delivering the vector to the target cell (Bobo et al., *Proc. Natl. Acad.*

Sci. USA, 91:2076-2080 (1994); Morrison et al., *Am. J. Physiol.*, 266:292-305

(1994)). Other methods that can be used include catheters, intravenous, parenteral,

intraperitoneal and subcutaneous injection, and oral or other known routes of

30   administration.

Parenteral formulations for administration of a neuregulin or a fragment or

derivative thereof may be in the form of liquid solutions or suspensions; for oral

- 16 -

administration, formulations may be in the form of tablets or capsules; and for

intranasal formulations, in the form of powders, nasal drops, or aerosols.

Methods well known in the art for making formulations are found in, for

example, "Remington's Pharmaceutical Sciences". Formulations for parenteral

5   administration may, for example, contain as excipients sterile water or saline,

polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or

hydrogenated naphthalenes, biocompatible, biodegradable lactide polymer, or

polyoxyethylene-polyoxypropylene copolymers may be used to control the release of

the present factors. Other potentially useful parenteral delivery systems for a

10   neuregulin or fragments or derivatives thereof include ethylene-vinyl acetate

copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.

Formulations for inhalation may contain as excipients, for example, lactose, or may be

aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether,

glycocholate and deoxycholate, or may be oily solutions for administration in the

15   form of nasal drops, or as a gel to be applied intranasally. Formulations for parenteral

administration may also include glycocholate for buccal administration,

methoxysalicylate for rectal administration, or citric acid for vaginal administration.

The concentration of a neuregulin or a fragment or derivative thereof, or

nucleic acid encoding such polypeptides, administered to a particular subject will vary

20   depending upon a number of issues, including the condition being treated, the mode

and site of administration, the age, weight sex and general health of the subject, and

other such factors that are recognized by those skilled in the art. Optimal

administration rates for a given protocol of administration can be readily determined

by those skilled in the art.

25   All documents mentioned herein are incorporated herein by reference in their

entirety. The invention is further illustrated by the following non-limiting Examples.

Example 1 -- In vivo neuroprotection assay

Neuregulins and neuregulin fragments and derivatives can be assessed for

neuroprotective efficacy pursuant to the following assay.

30   Mature male Long-Evans rats (Charles River, 250-350g) are allowed food and

water *ad libitum*. Animals are anesthetized with sodium pentobarbital (60 mg/kg, i.p.)

and placed in a stereotaxic head holder (David Kopf Instruments, Tujunga, CA). The

- 17 -

dorsal surface of the skull is exposed by midline incision, and a small burr hole (2 mm diameter) is drilled over the right lateral ventricle, 1.6 mm lateral and 0.9 mm posterior to bregma. A stainless steel cannula (I.D. 0.020", O.D. 0.028", 2 cm long) is then inserted stereotaxically into the ventricle to a depth of 4.4 mm beneath the

5　surface of the skull. The tubing is suitably bent at a 90° angle 1-1.6 cm from its tip and connected to polyethylene tubing (I.D. 0.76 mm, O.D. 1.22 mm, 10 cm long) that is connected (by glue) to a mini-osmotic pump (Alzet 1007D, 100 μl fill volume, pump rate = 0.5 μl/hr; Alza Corp., Palo Alto, CA) implanted subcutaneously in the back. The cannula can be suitably fixed to the skull by orthodontic resin (L.D. Culk

10　Co., Milford, DE) bonded to two small machine screws (1/8" stainless steel slotted) inserted in the skull. The pump, tubing, and cannula are primed before insertion with infusate solutions; a 3-0 nylon suture is inserted into the cannula during implantation to prevent obstruction by brain tissue. The wound is closed with 3-0 silk suture and cefazolin (10 mg, i.m.) is administered. After surgery animals are suitably kept in

15　individual cages and fed soft food.

Pumps are filled with vehicle alone (containing 127 mM NaCl, 2.6 mM KCl, 1.2 mM $CaCl_2$, 0.9 mM $MgCl_2$, 4.14 mM HEPES, 3 mM glycerin, 0.001% bovine serum albumin [BSA], and 0.01% fast green), or vehicle neuregulin or fragment or derivative thereof (100 μgm/ml). Heparin can be suitably used at relatively low

20　doses, e.g. about 0.8 units/kg/day which is approximately 250-500 times less than a standard anticoagulant dose.

Three days after cannula implantation, animals are reanesthetized with 2% halothane and given atropine (0.15 mg/kg, i.p.). Animals are then intubated and connected to a ventilator (SAR-830; CWE Inc., Ardmore, PA) delivering 1%

25　halothane/70% nitrous oxide in oxygen. The right femoral artery and vein are cannulated for monitoring of mean arterial blood pressure (MABP; Gould RS3200 Blood Pressure Monitor, Gould Inc., Valley View, OH), and blood sampling. Animals are then paralyzed with pancuronium bromide (0.5 mg/kg, i.v.). Arterial blood gasses (Corning 178 Blood Gas Analyzer, Ciba Corning Diagnostic Corp.,

30　Medford, MA), blood glucose (Accu-Check Blood Glucose Analyzer, Boehringer Mannheim, Indianapolis, IN), and hematocrit are measured at least twice during surgery and the immediate post-operative period. The stroke volume and rate of the

- 18 -

ventilator are adjusted to maintain PaO_2 between 100-200 mm Hg and $PaCO_2$ between 30-40 mm Hg. Core body temperature may be monitored by rectal thermocouple (e.g. Model 73ATA, Yellow Springs Instrument Co., Yellow Springs, OH) and maintained between 36-37°C with a homeothermic blanket control unit (Harvard Bioscience,

5   South Natick, MA).

Focal ischemic infarcts are made in the right lateral cerebral cortex in the territory of the middle cerebral artery (MCA) by the method of Chen, et al., *Stroke*, 17:738-743 (1986). Both common carotid arteries are exposed by midline anterior cervical incision. The animal is placed in a lateral position and a 1 cm skin incision is

10   then made at the midpoint between the right lateral canthus and the anterior pinna. The temporal muscle is retracted, and a small (3 mm diameter) craniectomy is made at the junction of the zygoma and squamosal bone using a dental drill cooled with saline. Using a dissecting microscope, the dura can be opened with fine forceps, and the right MCA can be ligated with two 10-0 monofilament nylon ties just above the rhinal

15   fissure and transected between the ties. Both common carotid arteries then can be occluded by microaneurysm clips for 45 minutes. After removal of the clips, return of flow is visualized in the arteries. Anesthesia is maintained for 15 minutes, and animals are returned to individual cages and fed soft food after surgery.

Twenty four hours after cerebral infarction, animals are again weighed, and

20   then sacrificed by rapid decapitation. Brains are removed, inspected visually for the anatomy of the middle cerebral artery as well as for signs of hemorrhage or infection, immersed in cold saline for 10 minutes, and sectioned into six standard coronal slices (each 2 mm thick) using a rodent brain matrix slicer (Systems, Warren, MI). Brains are also examined visually for the presence of dye (fast green) in the cerebral

25   ventricles. Slices are placed in the vital dye 2,3,5-triphenyl tetrazolium chloride (TTC, 2%; Chemical Dynamics Co., NH) at 37°C in the dark for 30 minutes, followed by 10% formalin at room temperature overnight. The outline of right and left cerebral hemispheres as well as that of infarcted tissue, clearly visualizable by lack of TTC staining (Chen et al., *Stroke*, 17:738-743 (1986)), is outlined on the posterior surface

30   of each slice using an image analyzer (MTI videocamera and Sony video monitor connected to a Bioquant IV Image Analysis System run on an EVEREX computer). Infarct volume is calculated as the sum of infarcted area per slice multiplied by slice

- 19 -

thickness. Both the surgeon and image analyzer operator are blinded to the treatment given each animal.

Volumes of infarcts among vehicle vs. neuregulin-treated animals can be compared by unpaired, two-tailed t-tests for each experiment, and by two-way

5   analysis of variance (ANOVA; Exp. X Treatment) for combined data. A subsequent slice-by-slice analysis of infarct area among pooled neuregulin- vs. vehicle-treated animals is suitably done by repeated measures two-way ANOVA (Treatment X Slice). Other anatomical and physiological measurements are compared among GDF-1- vs. vehicle-treated animals by unpaired, two-tailed t-tests using the Bonferroni correction

10   for multiple pairwise comparisons.

Example 2 -- In vivo behavioral assays

For behavioral outcome studies, such as to assess recovery, repair and remodeling promoted by administration of a neuregulin or fragment or derivative thereof, or nucleic acid encoding same, a number of assays can be employed such as

15   those described in G. Sinson et al., *J Neurochem*, 65(5):2209-2214 (1995); T.K. McIntosh et al., *Neuroscience*, 28:233-244 (1989); and T.K. McIntosh et al., *J Neurotrauma*, 10:373-384 (1993).

Briefly, one suitable behavioral assay as described in G. Sinson et al., *supra*, entails that test animals (male Sprague-Dawley rats) receive preinjury training in a

20   Morris Water Maze, a circular tank 1 m in diameter that is filled with 18°C water. The water surface is made opaque with a covering of Styrofoam pieces. During training of the animals a submerged platform is present in the maze. Each test animal undergoes 20 training trials over a two day period during which they learn to locate the platform using external visual cues. Immediately following the last training trial,

25   animals are anesthetized and subjected to a lateral (parasagittal) fluid-percussion (FP) brain injury. Briefly, a 5-mm craniectomy is performed over the left parietal cortex, midway between lamda and bregma. A hollow Leur-loc fitting is cemented to the craniectomy site. The injury is delivered after attaching the FP device. The injury should be of moderate severity (2.1-2.3 atm). After injury, the Leur-loc is removed,

30   and the skin is sutured. Normothermia is maintained with warming pads until the animals being to ambulate.

- 20 -

At 72 hours, 1 week or 2 weeks after injury, animals are assessed for their ability to remember the learned task of locating the platform in the MWM. For this evaluation the platform is removed from the maze, and the animal's swimming pattern is suitably recorded with a computerized video system for 1 minute. The maze is

5   separated in zones that are weighed according to the proximity to the platform's location. A memory score is generated by multiplying the weighted numbers by the time the animal spends in each zone and then adding the products.

Animals surviving for 1 or 2 weeks also can undergo evaluation of neurologic motor function. Briefly, one suitable assay provides that animals are scored from 0

10   (severely impaired) to 4 (normal) for each of the following: (1) left and (2) right forelimb during suspension by the tail; (3) left and (4) right hindlimb flexion when the forelimbs remain on a surface and the hindlimbs are lifted up and back by the tail; the ability to resist lateral pulsion to the (5) left and (6) right; and the ability to stand on an inclined plane in the (7) left, (8) right, and (9) vertical positions. Scores are

15   combined for each of the tests (1) through (9). The observer for the tests should be blinded to the animal's previous treatment.

The invention has been described in detail with reference to preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements

20   within the spirit and scope of the invention.

- 21 -

What is claimed is:

1.   A method of treating a mammal suffering from or susceptible to stroke, brain or spinal cord injury or ischemia, or heart attack, comprising administering to the mammal a therapeutically effective amount of a neuregulin, or fragment or derivative of a neuregulin, or a nucleic acid encoding a neuregulin or a fragment or derivative of a neuregulin.

2.   A method of treating a mammal suffering from or susceptible to optic nerve injury or retinal injury or ischemia, comprising administering to the mammal a therapeutically effective amount of a neuregulin, or fragment or derivative of a neuregulin, or a nucleic acid encoding a neuregulin or a fragment or derivative of a neuregulin.

3.   A method of treating a mammal suffering from or susceptible to effects of post-surgical neurological deficits, hypoxia or hypoglycemia, comprising administering to the mammal a therapeutically effective amount of a neuregulin, or fragment or derivative of a neuregulin, or a nucleic acid encoding a neuregulin or a fragment or derivative of a neuregulin.

4.   A method of treating a mammal suffering from or susceptible to epilepsy, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Alzheimer's disease, Down's Syndrome, Korsakoff's disease, or age-dependent dementia, comprising administering to the mammal a therapeutically effective amount of a neuregulin, or fragment or derivative of a neuregulin, or a nucleic acid encoding a neuregulin or a fragment or derivative of a neuregulin.

5.   The method of claim 1 wherein the neuregulin, or fragment or derivative of a neuregulin, or a nucleic acid encoding a neuregulin or a fragment or derivative of a neuregulin is administered after the subject has suffered a stroke, brain or spinal cord injury or ischemia, or heart attack.

6.   The method of claim 5 wherein the neuregulin, or fragment or derivative of a neuregulin, or a nucleic acid encoding a neuregulin or a fragment or derivative of a neuregulin is administered to the subject for at least about two weeks after the subject has suffered a stroke, brain or spinal cord injury or ischemia, or heart attack.

- 22 -

7.   A method of any one of claims 1-6 wherein a neuregulin or a fragment or derivative thereof is administered to the mammal.

8.   A method of claim 7 wherein the neuregulin or fragment or derivative thereof comprises an amino acid sequence of the following formula:

WYBAZCX

wherein WYBAZCX is composed of amino acid sequences that include one or more sequences shown in FIGS. 1 through 15 (which includes SEQ ID NOS:2, 4, 5, 8, 9, 12, 14, 15, 18, 19, 22, 23, 26, 27, 30, 33, 35, 38, 39, 41, 44, 45 and 48), wherein W comprises the polypeptide segment F, or is absent; wherein Y comprises the polypeptide segment E, or is absent; wherein Z comprises the polypeptide segment G or is absent; and wherein X comprise a polypeptide segment selected from the group consisting of C/D HKL, C/D H, C/D HL, C/D D, C/D' HL, C/D' HKL, C/D' H, C/D' D, C/D C/D' HKL, C/D C/D' H, C/D C/D' HL, C/D C/D' D, C/d D'H, C/D D' HL, C/D D' HKL, C/D' D' H, C/D' D' HL, C/D' D' HKL, C/D C/D' D' H, C/D C/D' D' HL and C/D C/D' D' HKL, and preferably that either

        a)   at least one of F, Y, B, A, Z, C or X is of bovine origin; or

        b)   Y comprises the polypeptide segment E; or

        c)   X comprises the polypeptide segments C/D HKL, C/D D, C/D' HKL, C/D C/D' HKL, C/D C/D' D, C/D D' H, C/D D' HL, C/D D' HKL, C/D' D' H, C/D' D' HKL, C/D C/D' D'H, C/D C/D' D HL, C/D C/D' D' HKL, C/D'H, C/D C/D' H or C/D C/D' HL.

9.   The method of claim 7 wherein the neuregulin or fragment or derivative thereof a) has at least one of F, Y, B, A, Z, C or X is of bovine origin; or b) Y comprises the polypeptide segment E; or c) X comprises the polypeptide segments C/D HKL, C/D D, C/D' HKL, C/D C/D' HKL, C/D C/D' D, C/D D H, C/D D' HL, C/D D' HKL, C/D C/D' D' H, C/D C/D' D HL, C/D C/D' D' HKL, C/D'H, C/D C/D' H or C/D C/D' HL.

10.   The method of claim 7 wherein the neuregulin or fragment or derivative thereof comprises FBA polypeptide segments, FEBA polypeptides segments, EBA polypeptide segments, EBA' polypeptide segments or FEBA' polypeptide segments.

- 23 -

11. A method of claim 7 wherein the neuregulin is encoded by a nucleic acid that comprises one of SEQ ID NOS:49, 51 and 53.

12. A method of claim 7 wherein the neuregulin or fragment or derivative thereof is encoded by a nucleic acid that comprises a sequence that has at least about 70% sequence identity to one of SEQ ID NOS:49, 51 and 53.

13. A method of claim 7 wherein the neuregulin or fragment or derivative thereof is encoded by a sequence that hybridizes to one of SEQ ID NOS:49, 51 or 53 under normal stringency conditions.

14. A method of claim 7 wherein the neuregulin or fragment or derivative thereof is encoded by a sequence that hybridizes to one of SEQ ID NOS:49, 51 or 53 under high stringency conditions.

15. A method of claim 7 wherein the neuregulin or fragment or derivative has at least about 70% sequence identity to SEQ ID NOS:50, 52 or 54.

16. A method of claim 7 wherein the neuregulin or fragment or derivative thereof is encoded by a nucleic acid that comprises a sequence that has at least about 70% sequence identity to one of SEQ ID NO:20 (Figure 7); SEQ ID NO:21 (Figure 7); SEQ ID NO:24 (Figure 8); SEQ ID NO:25 (Figure 8); SEQ ID NO:28 (Figure 9); or SEQ ID NO:29 (Figure 9).

17. A method of claim 7 wherein the neuregulin or fragment or derivative thereof is encoded by a sequence that hybridizes to one of SEQ ID NO:20 (Figure 7); SEQ ID NO:21 (Figure 7); SEQ ID NO:24 (Figure 8); SEQ ID NO:25 (Figure 8); SEQ ID NO:28 (Figure 9); or SEQ ID NO:29 (Figure 9) under normal stringency conditions.

18. A method of claim 7 wherein the neuregulin or fragment or derivative comprises a sequence that has at least about 70% sequence identity to any of the peptide sequences shown in Figures 7, 8 or 9 of the drawings.

19. A method of claim 7 where the neuregulin or fragment or derivative comprises a sequence that has at least about 80 percent homology to any of the peptide sequences shown in Figures 7, 8 or 9.

20. A method of claim 7 where the neuregulin or fragment or derivative comprises a sequence that has at least about 90 percent homology to any of the peptide sequences shown in Figures 7, 8 or 9.

- 24 -

21.   A method of claim 7 wherein the neuregulin or fragment or derivative comprises a sequence that has at least about 95 percent homology to any of the peptide sequences shown in Figures 7, 8 or 9.

22.   A method of claim 7 wherein the neuregulin or fragment or derivative comprises a sequence that is shown in Figures 7, 8 or 9.

23.   A method of any one of claims 1-6 wherein a nucleic acid encoding a neuregulin or a fragment or derivative thereof is administered to the mammal.

24.   A method of claim 23 wherein the nucleic acid is SEQ ID NO:49, 51 or 53, or the complement thereof.

25.   A method of claim 23 wherein the nucleic or fragment or derivative thereof encodes a neuregulin or neuregulin fragment or derivative that comprises an amino acid sequence of the following formula:

WYBAZCX

wherein WYBAZCX is composed of amino acid sequences that include one or more sequences shown in FIGS. 1 through 15 (which includes SEQ ID NOS:2, 4, 5, 8, 9, 12, 14, 15, 18, 19, 22, 23, 26, 27, 30, 33, 35, 38, 39, 41, 44, 45 and 48), wherein W comprises the polypeptide segment F, or is absent, wherein Y comprises the polypeptide segment E, or is absent; wherein Z comprises the polypeptide segment G or is absent; and wherein X comprise a polypeptide segment selected from the group consisting of C/D HKL, C/D H, C/D HL, C/D D, C/D' HL, C/D' HKL, C/D' H, C/D' D, C/D C/D' HKL, C/D C/D' H, C/D C/D' HL, C/D C/D' D, C/D D' HL, C/D D' HKL, C/D' D' H, C/D' D' HL, C/D' D' HKL, C/D C/D' D' H, C/D C/D' D' HL and C/D C/D' D' HKL.

26.   The method of claim 25 wherein the neuregulin or neuregulin fragment or derivative a) has at least one of F, Y, B, A, Z, C or X is of bovine origin; or b) Y comprises the polypeptide segment E; or c) X comprises the polypeptide segments C/D HKL, C/D D, C/D' HKL, C/D C/D' HKL, C/D C/D' D, C/D D H, C/D D' HL, C/D D' HKL, C/D C/D' D' H, C/D C/D' D HL, C/D C/D' D' HKL, C/D'H, C/D C/D' H or C/D C/D' HL.

27.   The method of claim 25 wherein the neuregulin or neuregulin fragment or derivative comprises FBA polypeptide segments, FEBA polypeptides segments,

- 25 -

EBA' polypeptide segments, EBA' polypeptide segments or FEBA' polypeptide segments.

28.   A method of claim 23 wherein the nucleic acid comprises a sequence that hybridizes to SEQ ID NO:20 (Figure 7); SEQ ID NO:21 (Figure 7); SEQ ID NO:24 (Figure 8); SEQ ID NO:25 (Figure 8); SEQ ID NO:28 (Figure 9); or SEQ ID NO:29 (Figure 9) under normal stringency conditions.

29.   A method of claim 23 wherein the nucleic acid comprises a sequence that hybridizes to SEQ ID NO:SEQ ID NO:20 (Figure 7); SEQ ID NO:21 (Figure 7); SEQ ID NO:24 (Figure 8); SEQ ID NO:25 (Figure 8); SEQ ID NO:28 (Figure 9); or SEQ ID NO:29 (Figure 9) under high stringency conditions.

30.   A method of claim 23 wherein the nucleic acid comprises a sequence that has at least about 70 percent homology to any of the nucleic acid sequences shown in Figures 7, 8 or 9.

31.   A method of claim 23 wherein the nucleic acid comprises a sequence that has at least about 80 percent homology to any of the nucleic acid sequences shown in Figures 7, 8 or 9.

32.   A method of claim 23 wherein the nucleic acid comprises a sequence that has at least about 90 percent homology to any of the nucleic acid sequences shown in Figures 7, 8 or 9.

33.   A method of claim 23 wherein the nucleic acid comprises a sequence that has at least about 95 percent homology to any of the nucleic acid sequences shown in Figures 7, 8 or 9.

34.   A method of claim 23 wherein the nucleic acid comprises a sequence shown in Figures 7, 8 or 9.

35.   A method of any one of claims 1-34 wherein the administered neuregulin fragment or derivative, or the administered nucleic acid encodes a neuregulin fragment or derivative exhibits at least about a 10% reduction in infarct volume in an *in vivo* cerebral ischemia assay.

36.   A method of any one of claims 1-35 wherein the mammal is a human.

FIG. 1A
HUMAN SEGMENT E: (SEQ ID NOS:1-2)

```
ATG AGA TGG CGA CGC GCC CCG CGC CGC TCC GGG CGT CCC GGC CCC CGG        48
Met Arg Trp Arg Arg Ala Pro Arg Arg Ser Gly Arg Pro Gly Pro Arg
1                   5                   10                  15

GCC CAG CGC CCC GGC TCC GCC GCC CGC TCG TCG CCG CCG CTG CCG CTG        96
Ala Gln Arg Pro Gly Ser Ala Ala Arg Ser Ser Pro Pro Leu Pro Leu
                20                  25                  30

CTG CCA CTA CTG CTG CTG CTG GGG ACC GCG GCC CTG GCG CCG GGG GCG       144
Leu Pro Leu Leu Leu Leu Leu Gly Thr Ala Ala Leu Ala Pro Gly Ala
            35                  40                  45

GCG GCC GGC AAC GAG GCG GCT CCC GCG GGG GCC TCG GTG TGC TAC TCG       192
Ala Ala Gly Asn Glu Ala Ala Pro Ala Gly Ala Ser Val Cys Tyr Ser
        50                  55                  60

TCC CCG CCC AGC GTG GGA TCG GTG CAG GAG CTA GCT CAG CGC GCC GCG       240
Ser Pro Pro Ser Val Gly Ser Val Gln Glu Leu Ala Gln Arg Ala Ala
65                  70                  75                  80

GTG GTG ATC GAG GGA AAG GTG CAC CCG CAG CGG CGG CAG CAG GGG GCA       288
Val Val Ile Glu Gly Lys Val His Pro Gln Arg Arg Gln Gln Gly Ala
                85                  90                  95

CTC GAC AGG AAG GCG GCG GCG GCG GCG GGC GAG GCA GGG GCG TGG GGC       336
Leu Asp Arg Lys Ala Ala Ala Ala Ala Gly Glu Ala Gly Ala Trp Gly
                100                 105                 110

GGC GAT CGC GAG CCG CCA GCC GCG GGC CCA CGG GCG CTG GGG CCG CCC       384
Gly Asp Arg Glu Pro Pro Ala Ala Gly Pro Arg Ala Leu Gly Pro Pro
            115                 120                 125

GCC GAG GAG CCG CTG CTC GCC GCC AAC GGG ACC GTG CCC TCT TGG CCC       432
Ala Glu Glu Pro Leu Leu Ala Ala Asn Gly Thr Val Pro Ser Trp Pro
        130                 135                 140

ACC GCC CCG GTG CCC AGC GCC GGC GAG CCC GGG GAG GAG GCG CCC TAT       480
Thr Ala Pro Val Pro Ser Ala Gly Glu Pro Gly Glu Glu Ala Pro Tyr
145                 150                 155                 160

CTG GTG AAG GTG CAC CAG GTG TGG GCG GTG AAA GCC GGG GGC TTG AAG       528
Leu Val Lys Val His Gln Val Trp Ala Val Lys Ala Gly Gly Leu Lys
                165                 170                 175

AAG GAC TCG CTG CTC ACC GTG CGC CTG GGG ACC TGG GGC CAC CCC GCC       576
Lys Asp Ser Leu Leu Thr Val Arg Leu Gly Thr Trp Gly His Pro Ala
            180                 185                 190
```

FIG. 1B

```
TTC CCC TCC TGC GGG AGG CTC AAG GAG GAC AGC AGG TAC ATC TTC TTC          624
Phe Pro Ser Cys Gly Arg Leu Lys Glu Asp Ser Arg Tyr Ile Phe Phe
        195                 200             205

ATG GAG CCC GAC GCC AAC AGC ACC AGC CGC GCG CCG GCC GCC TTC CGA          672
Met Glu Pro Asp Ala Asn Ser Thr Ser Arg Ala Pro Ala Ala Phe Arg
        210                 215             220

GCC TCT TTC CCC CCT CTG GAG ACG GGC CGG AAC CTC AAG AAG GAG GTC          720
Ala Ser Phe Pro Pro Leu Glu Thr Gly Arg Asn Leu Lys Lys Glu Val
225                 230             235                 240

AGC CGG GTG CTG TGC AAG CGG TGC G                                        745
Ser Arg Val Leu Cys Lys Arg Cys
                245
```

3/18

FIG.2
SEGMENT E: (SEQ ID NOS:3-4)

```
CC CAT CAA GTG TGG GCG GCG AAA GCC GGG GGC TTG AAG AAG GAC TCG        47
   His Gln Val Trp Ala Ala Lys Ala Gly Gly Leu Lys Lys Asp Ser
    1               5                  10                  15

CTG CTC ACC GTG CGC CTG GGC GCC TGG GGC CAC CCC GCC TTC CCC TCC       95
Leu Leu Thr Val Arg Leu Gly Ala Trp Gly His Pro Ala Phe Pro Ser
                20                  25                  30

TGC GGG CGC CTC AAG GAG GAC AGC AGG TAC ATC TTC TTC ATG GAG CCC       143
Cys Gly Arg Leu Lys Glu Asp Ser Arg Tyr Ile Phe Phe Met Glu Pro
            35                  40                  45

GAG GCC AAC AGC AGC GGC GGG CCC GGC CGC CTT CCG AGC CTC CTT CCC       191
Glu Ala Asn Ser Ser Gly Gly Pro Gly Arg Leu Pro Ser Leu Leu Pro
            50                  55                  60

CCC TCT CGA GAC GGG CCG GAA CCT CAA GAA GGA GGT CAG CCG GGT GCT       239
Pro Ser Arg Asp Gly Pro Glu Pro Gln Glu Gly Gly Gln Pro Gly Ala
        65                  70                  75

GTG CAA CGG TGC G                                                     252
Val Gln Arg Cys
80
```

FIG. 3
SEGMENT B: (SEQ ID NOS:5-8)

```
Leu Pro Pro Arg Leu Lys Glu His Lys Ser Gln Glu Ser Val Ala Gly
CCT TGC CTC CCC GCT TGA AAG AGA TGA AGA GTC AGG AGT CTG TGG CAG        48
||| ||| ||| ||| |  | ||| ||| ||| ||| |  |  | ||| |  | |  |  | |||
CCT TGC CTC CCC GAT TGA AAG AGA TGA AAA GCC AGG AAT CGG CTG CAG
            Q                                       A

Ser Lys Leu Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser Ser Leu
GTT CCA AAC TAG TGC TTC GGT GCG AGA CCA GTT CTG AAT ACT CCT CTC        96
||| ||| ||| ||| |  | ||| ||| |  | |  | ||| ||| ||| ||| ||| |||
GTT CCA AAC TAG TCC TTC GGT GTG AAA CCA GTT CTG AAT ACT CCT CTC

Lys Phe Lys Trp Phe Lys Asn Gly Ser Glu Leu Ser Arg Lys Asn Lys
TCA AGT TCA AGT GGT TCA AGA ATG GGA GTG AAT TAA GCC GAA AGA ACA       144
||| |  | ||| ||| ||| ||| ||| ||| ||| |  | ||| |  | ||| |  | |||
TCA GAT TCA AGT GGT TCA AGA ATG GGA ATG AAT TGA ATC GAA AAA ACA
R                               N           N

Pro Gly Asn Ile Lys Ile Gln Lys Arg Pro Gly
AAC CAC AAA ACA TCA AGA TAC AGA AAA GGC CGG G                         178
||| ||| ||| |  | ||| ||| ||| |  | ||| |  | |  |
AAC CAC AAA ATA TCA AGA TAC AAA AAA AGC CAG G
                                        K
```

FIG 4
SEGMENT A: (SEQ ID NOS:9-12)

```
  Lys Ser Glu Leu Arg Ile Ser Lys Ala Ser Leu Ala Asp Ser Gly
G AAG TCA GAA CTT CGC ATT AGC AAA GCG TCA CTG GCT GAT TCT GGA      46
  ||| ||| ||| ||| ||| ||| || ||| || ||| ||| ||| ||| ||| ||
G AAG TCA GAA CTT CGC ATT AAC AAA GCA TCA CTG GCT GAT TCT GGA
                           N
```

```
  Glu Tyr Met Cys Lys Val Ile Ser Lys Leu Gly Asn Asp Ser Ala Ser
  GAA TAT ATG TGC AAA GTG ATC AGC AAA CTA GGA AAT GAC AGT GCC TCT      94
  || ||| ||| ||| ||| ||| ||| ||| ||| _|| ||| ||| ||| ||| ||| |||
  GAG TAT ATG TGC AAA GTG ATC AGC AAA TTA GGA AAT GAC AGT GCC TCT
```

```
  Ala Asn Ile Thr Ile Val Glu Ser Asn Ala
  GCC AAC ATC ACC ATT GTG GAG TCA AAC G      122
  ||| || ||| ||| || ||| || ||| ||| |
  GCC AAT ATC ACC ATC GTG GAA TCA AAC G
```

FIG.5
SEGMENT A': (SEQ ID NOS:13-14)

```
TCTAAAACTA CAGAGACTGT ATTTTCATGA TCATCATAGT TCTGTGAAAT ATACTTAAAC      60
```

```
CGCTTTGGTC CTGATCTTGT AGG AAG TCA GAA CTT CGC ATT AGC AAA GCG      110
                          Lys Ser Glu Leu Arg Ile Ser Lys Ala
                           1                   5
```

```
TCA CTG GCT GAT TCT GGA GAA TAT ATG TGC AAA GTG ATC AGC AAA CTA      158
Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys Lys Val Ile Ser Lys Leu
 10                15                 20                    25
```

```
GGA AAT GAC AGT GCC TCT GCC AAC ATC ACC ATT GTG GAG TCA AAC GGT      206
Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr Ile Val Glu Ser Asn Gly
               30                 35                     40
```

```
AAG AGA TGC CTA CTG CGT GCT ATT TCT CAG TCT CTA AGA GGA GTG ATC      254
Lys Arg Cys Leu Leu Arg Ala Ile Ser Gln Ser Leu Arg Gly Val Ile
               45                 50                     55
```

```
AAG GTA TGT GGT CAC ACT TGAATCACGC AGGTGTGTGA AATCTCATTG      302
Lys Val Cys Gly His Thr
               60
```

```
TGAACAAATA AAAATCATGA AAGGAAAACT CTATGTTTGA AATATCTTAT GGGTCCTCCT      362
```

```
GTAAAGCTCT TCACTCCATA AGGTGAAATA GACCTGAAAT ATATATAGAT TATTT      417
```

FIG. 6
SEGMENT G: (SEQ ID NOS:15-18)

```
Glu Ile Thr Thr Gly Met Pro Ala Ser Thr Glu Thr Ala Tyr Val Ser
 AG ATC ACC ACT GGC ATG CCA GCC TCA ACT GAG ACA GCG TAT GTG TCT      47
 ││ │││ │ │ │││ ││  │││ │││ │││ │││ ││ ││  │  ││ │││ │││ │││
 AG ATC ATC ACT GGT ATG CCA GCC TCA ACT GAA GGA GCA TAT GTG TCT
         I                           G

Ser Glu Ser Pro Ile Arg Ile Ser Val Ser Thr Glu Gly Thr Asn Thr
TCA GAG TCT CCC ATT AGA ATA TCA GTA TCA ACA GAA GGA ACA AAT ACT      95
│││ │││ │││ │││ │││ │││ │││ │││ │││ ││  │││ │││ │││ ││  │││ │││
TCA GAG TCT CCC ATT AGA ATA TCA GTA TCC ACA GAA GGA GCA AAT ACT
                                                     A

Ser Ser Ser
TCT TCA T                                                            102
│││ │││ │
TCT TCA T
```

FIG. 7
SEGMENT C: (SEQ ID NOS:19-22)

```
   Thr Ser Thr Ser Thr Ala Gly Thr Ser His Leu Val Lys Cys Ala
CC ACA TCC ACA TCT ACA GCT GGG ACA AGC CAT CTT GTC AAG TGT GCA      47
│  │││ ││  │││ ││  ││  ││ │││ │││ │││ │││ │││ ││  ││  │││ ││
CT ACA TCT ACA TCC ACC ACT GGG ACA AGC CAT CTT GTA AAA TGT GCG
       T

Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys Phe Met Val
GAG AAG GAG AAA ACT TTC TGT GTG AAT GGA GGC GAG TGC TTC ATG GTG      95
│││ │││ │││ │││ │││ │││ │││ │││ │││ │││ ││  │││ │││ │││ │││ │││
GAG AAG GAG AAA ACT TTC TGT GTG AAT GGA GGG GAG TGC TTC ATG GTG

Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys
AAA GAC CTT TCA AAT CCC TCA AGA TAC TTG TGC                         128
│││ │││ │││ │││ ││  │││ ││  │││ │││ │││ │││
AAA GAC CTT TCA AAC CCC TCG AGA TAC TTG TGC
```

SUBSTITUTE SHEET (RULE 26)

FIG. 8
SEGMENT C/D: (SEQ ID NOS:23-26)

```
Lys Cys Gln Pro Gly Phe Thr Gly Ala Arg Cys Thr Glu Asn Val Pro
AAG TGC CAA CCT GGA TTC ACT GGA GCG AGA TGT ACT GAG AAT GTG CCC     48
||| ||| ||| ||| ||| ||| ||| ||| ||  ||| ||| ||| ||| ||| ||| |||
AAG TGC CAA CCT GGA TTC ACT GGA GCA AGA TGT ACT GAG AAT GTG CCC
```

```
Met Lys Val Gln Thr Gln Glu
ATG AAA GTC CAA ACC CAA GAA                                        69
||| ||| ||| ||| || ||| |||
ATG AAA GTC CAA AAC CAA GAA
             N
```

FIG. 9
SEGMENT C/D': (SEQ ID NOS:27-29)

```
Lys Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val Met
AAG TGC CCA AAT GAG TTT ACT GGT GAT CGC TGC CAA AAC TAC GTA ATG     48
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
AAG TGC CCA AAT GAG TTT ACT GGT GAT CGC TGC CAA AAC TAC GTA ATG
```

```
Ala Ser Phe Tyr
GCC AGC TTC TAC                                                     60
||| ||| ||| |||
GCC AGC TTC TAC
```

FIG. 10
SEGMENT D: (SEQ ID NOS:30-32)

```
Ser Thr Ser Thr Pro Phe Leu Ser Leu Pro Glu  *
AGT ACG TCC ACT CCC TTT CTG TCT CTG CCT GAA TAG                    36
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
AGT ACG TCC ACT CCC TTT CTG TCT CTG CCT GAA TAG
```

FIG. 11
SEGMENT D': (SEQ ID NOS:33-34)

```
Lys His Leu Gly Ile Glu Phe Met Glu
AAG CAT CTT GGG ATT GAA TTT ATG GAG                                    27
```

FIG. 12A
SEGMENT H: (SEQ ID NOS:35-38)

```
Lys Ala Glu Glu Leu Tyr Gln Lys Arg Val Leu Thr Ile Thr Gly Ile
AAA GCG GAG GAG CTC TAC CAG AAG AGA GTG CTC ACC ATT ACC GGC ATT       48
||| ||| ||| ||| || ||| ||| ||| ||| ||| || ||| || ||| ||| ||
AAA GCG GAG GAG CTG TAC CAG AAG AGA GTG CTG ACC ATA ACC GGC ATC

Cys Ile Ala Leu Leu Val Val Gly Ile Met Cys Val Val Val Tyr Cys
TGC ATC GCG CTG CTC GTG GTT GGC ATC ATG TGT GTG GTG GTC TAC TGC       96
||| ||| || || || ||| || ||| ||| ||| ||| ||| ||| || ||| |||
TGC ATC GCC CTC CTT GTG GTC GGC ATC ATG TGT GTG GTG GCC TAC TGC
                                         A

Lys Thr Lys Lys Gln Arg Lys Lys Leu His Asp Arg Leu Arg Gln Ser
AAA ACC AAG AAA CAA CGG AAA AAG CTT CAT GAC CGG CTT CGG CAG AGC       144
||| ||| ||| ||| || ||| ||| ||| || ||| ||| || ||| ||| ||| |||
AAA ACC AAG AAA CAG CGG AAA AAG CTG CAT GAC CGT CTT CGG CAG AGC

Leu Arg Ser Glu Arg Asn Thr Met Met Asn Val Ala Asn Gly Pro His
CTT CGG TCT GAA AGA AAC ACC ATG ATG AAC GTA GCC AAC GGG CCC CAC      192
||| ||| ||| ||| || ||| | ||| ||| ||| | ||| || ||| || |||
CTT CGG TCT GAA CGA AAC AAT ATG ATG AAC ATT GCC AAT GGG CCT CAC
                     N                  I

His Pro Asn Pro Pro Pro Glu Asn Val Gln Leu Val Asn Gln Tyr Val
CAC CCC AAT CCG CCC CCC GAG AAC GTG CAG CTG GTG AAT CAA TAC GTA      240
|| || || || ||| ||| ||| || || ||| ||| ||| ||| ||| ||| |||
CAT CCT AAC CCA CCC CCC GAG AAT GTC CAG CTG GTG AAT CAA TAC GTA

Ser Lys Asn Val Ile Ser Ser Glu His Ile Val Glu Arg Glu Ala Glu
TCT AAA AAT GTC ATC TCT AGC GAG CAT ATT GTT GAG AGA GAG GCG GAG      288
||| ||| || ||| ||| || || ||| ||| ||| ||| ||| ||| || || |||
TCT AAA AAC GTC ATC TCC AGT GAG CAT ATT GTT GAG AGA GAA GCA GAG

Ser Ser Phe Ser Thr Ser His Tyr Thr Ser Thr Ala His His Ser Thr
AGC TCT TTT TCC ACC AGT CAC TAC ACT TCG ACA GCT CAT CAT TCC ACT      336
| || ||| ||| ||| ||| ||| || ||| || ||| || ||| || ||| |||
ACA TCC TTT TCC ACC AGT CAC TAT ACT TCC ACA GCC CAT CAC TCC ACT
T
```

8/18

FIG. 12B

```
Thr Val Thr Gln Thr Pro Ser His Ser Trp Ser Asn Gly His Thr Glu
ACT GTC ACT CAG ACT CCC AGT CAC AGC TGG AGC AAT GGA CAC ACT GAA        384
||| ||| ||  ||| ||| ||  ||  ||| ||| ||| ||| ||  ||| ||| ||| |||
ACT GTC ACC CAG ACT CCT AGC CAC AGC TGG AGC AAC GGA CAC ACT GAA
```

```
Ser Ile Ile Ser Glu Ser His Ser Val Ile Val Met Ser Ser Val Glu
AGC ATC ATT TCG GAA AGC CAC TCT GTC ATC GTG ATG TCA TCC GTA GAA        432
||| |||  || ||  ||| ||| ||| ||| ||  ||| ||| ||| ||| ||| ||| |||
AGC ATC CTT TCC GAA AGC CAC TCT GTA ATC GTG ATG TCA TCC GTA GAA
         L
```

```
Asn Ser Arg His Ser Ser Pro Thr Gly Gly Pro Arg Gly Arg Leu Asn
AAC AGT AGG CAC AGC AGC CCG ACT GGG GGC CCG AGA GGA CGT CTC AAT        480
||| ||| ||| ||| ||| ||| ||  ||| ||| ||| ||  ||| ||| ||| ||  |||
AAC AGT AGG CAC AGC AGC CCA ACT GGG GGC CCA AGA GGA CGT CTT AAT
```

```
Gly Leu Gly Gly Pro Arg Glu Cys Asn Ser Phe Leu Arg His Ala Arg
GGC TTG GGA GGC CCT CGT GAA TGT AAC AGC TTC CTC AGG CAT GCC AGA        528
|||     ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
GGC ACA GGA GGC CCT CGT GAA TGT AAC AGC TTC CTC AGG CAT GCC AGA
    T
```

```
Glu Thr Pro Asp Ser Tyr Arg Asp Ser Pro His Ser Glu Arg
GAA ACC CCT GAC TCC TAC CGA GAC TCT CCT CAT AGT GAA AG                 569
||| ||| ||| ||  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
GAA ACC CCT GAT TCC TAC CGA GAC TCT CCT CAT AGT GAA AG
```

FIG. 13
SEGMENT K: (SEQ ID NOS:39-40)

```
A CAT AAC CTT ATA GCT GAG CTA AGG AGA AAC AAG GCC CAC AGA TCC        46
  His Asn Leu Ile Ala Glu Leu Arg Arg Asn Lys Ala His Arg Ser
   1           5                   10                  15
```

```
AAA TGC ATG CAG ATC CAG CTT TCC GCA ACT CAT CTT AGA GCT TCT TCC    94
Lys Cys Met Gln Ile Gln Leu Ser Ala Thr His Leu Arg Ala Ser Ser
             20                  25                  30
```

```
ATT CCC CAT TGG GCT TCA TTC TCT AAG ACC CCT TGG CCT TTA GGA AG     141
Ile Pro His Trp Ala Ser Phe Ser Lys Thr Pro Trp Pro Leu Gly Arg
             35                  40                  45
```

FIG. 14A
SEGMENT L: (SEQ ID NOS:41-44)

```
    Tyr Val Ser Ala Met Thr Thr Pro Ala Arg Met Ser Pro Val Asp
  G TAT GTA TCA GCA ATG ACC ACC CCG GCT CGT ATG TCA CCT GTA GAT        46
  | ||| ||  ||| ||  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
  G TAT GTG TCA GCC ATG ACC ACC CCG GCT CGT ATG TCA CCT GTA GAT

    Phe His Thr Pro Ser Ser Pro Lys Ser Pro Pro Ser Glu Met Ser Pro
    TTC CAC ACG CCA AGC TCC CCC AAG TCA CCC CCT TCG GAA ATG TCC CCG    94
    ||| ||| ||| ||| ||| ||| ||| || || ||| ||| ||| ||| ||| ||| ||
    TTC CAC ACG CCA AGC TCC CCC AAA TCG CCC CCT TCG GAA ATG TCT CCA

    Pro Val Ser Ser Thr Thr Val Ser Met Pro Ser Met Ala Val Ser Pro
    CCC GTG TCC AGC ACG ACG GTC TCC ATG CCC TCC ATG GCG GTC AGT CCC   142
    ||| ||| ||| ||| | ||| || ||| ||| || ||| ||| ||| ||| || |||
    CCC GTG TCC AGC ATG ACG GTG TCC ATG CCT TCC ATG GCG GTC AGC CCC
                    M

    Phe Val Glu Glu Glu Arg Pro Leu Leu Leu Val Thr Pro Pro Arg Leu
    TTC GTG GAA GAG GAG AGA CCC CTG CTC CTT GTG ACG CCA CCA CGG CTG   190
    ||| || ||| || ||| ||| || || || || ||| || ||| ||| || |||
    TTC ATG GAA GAA GAG AGA CCT CTA CTT CTC GTG ACA CCA CCA AGG CTG
        N

    Arg Glu Lys  -  Tyr Asp His His Ala Gln Gln Phe Asn Ser Phe His
    CGG GAG AAG ... TAT GAC CAC CAC GCC CAG CAA TTC AAC TCG TTC CAC   238
    ||| ||| ||| | ||| || ||| | ||| || ||| | || ||| |||
    CGG GAG AAG AAG TTT GAC CAT CAC CCT CAG CAG TTC AGC TCC TTC CAC
            K   F               P

    Cys Asn Pro Ala His Glu Ser Asn Ser Leu Pro Pro Ser Pro Leu Arg
    TGC AAC CCC GCG CAT GAG AGC AAC AGC CTG CCC CCC AGC CCC TTG AGG   286
    | ||| ||| ||| ||| || || ||| ||| || || | ||| ||| ||| |||
    CAC AAC CCC GCG CAT GAC AGT AAC AGC CTC CCT GCT AGC CCC TTG AGG
    N                   D                       A

    Ile Val Glu Asp Glu Glu Tyr Glu Thr Thr Gln Glu Tyr Glu Pro Ala
    ATA GTG GAG GAT GAG GAA TAT GAA ACG ACC CAG GAG TAC GAA CCA GCT   334
    ||| ||| ||| ||| ||| || ||| ||| ||| ||| || ||| ||| || ||| ||
    ATA GTG GAG GAT GAG GAG TAT GAA ACG ACC CAA GAG TAC GAG CCA GCC

    Gln Glu Pro Val Lys Lys Leu Thr Asn Ser Ser Arg Arg Ala Lys Arg
    CAA GAG CCG GTT AAG AAA CTC ACC AAC AGC AGC CGG CGG GCC AAA AGA   382
    ||| ||| || ||| ||| ||| ||| || ||| ... ||| ||| ||| ||| ||| |||
    CAA GAG CCT GTT AAG AAA CTC GCC AA. ..T AGC CGG CGG GCC AAA AGA
                                A
```

FIG. 14B

```
Thr Lys Pro Asn Gly His Ile Ala His Arg Leu Glu Met Asp Asn Asn
ACC AAG CCC AAT GGT CAC ATT GCC CAC AGG TTG GAA ATG GAC AAC AAC          430
||| ||| ||| ||| ||  ||| |||  ||   ||  ||  ||| |||  || |||  | |  |||
ACC AAG CCC AAT GGC CAC ATT GCT AAC AGA TTG GAA GTG GAC AGC AAC
                                N                    V       S
```

```
Thr Gly Ala Asp Ser Ser Asn Ser Glu Ser Glu Thr Glu Asp Glu Arg
ACA GGC GCT GAC AGC AGT AAC TCA GAG AGC GAA ACA GAG GAT GAA AGA          478
||| ||   |    |  ||| ||| ||| ||| ||| ||  ||| |||  || ||| ||| |||
ACA AGC TCC CAG AGC AGT AAC TCA GAG AGT GAA ACA GAA GAT GAA AGA
     S   S   Q
```

```
Val Gly Glu Asp Thr Pro Phe Leu Ala Ile Gln Asn Pro Leu Ala Ala
GTA GGA GAA GAT ACG CCT TTC CTG GCC ATA CAG AAC CCC CTG GCA GCC          526
||| ||  ||| ||| ||| ||| ||| ||| ||  ||| ||| ||| ||| ||| ||| |||
GTA GGT GAA GAT ACG CCT TTC CTG GGC ATA CAG AAC CCC CTG GCA GCC
                                G
```

```
Ser Leu Glu Ala Ala Pro Ala Phe Arg Leu Val Asp Ser Arg Thr Asn
AGT CTC GAG GCG GCC CCT GCC TTC CGC CTG GTC GAC AGC AGG ACT AAC          574
||| ||  ||| ||  ||   ||| ||| ||| ||| ||| |   ||| ||| ||| ||| |||
AGT CTT GAG GCA ACA CCT GCC TTC CGC CTG GCT GAC AGC AGG ACT AAC
                T                           A
```

```
Pro Thr Gly Gly Phe Ser Pro Gln Glu Glu Leu Gln Ala Arg Leu Ser
CCA ACA GGC GGC TTC TCT CCG CAG GAA GAA TTG CAG GCC AGG CTC TCC          622
||| ||  |||  || ||| ||   |  ||| ||| ||| |   ||| ||| ||| ||  ||
CCA GCA GGC CGC TTC TCG ACA CAG GAA GAA ATC CAG GCC AGG CTG TCT
     A           R           T               I
```

```
Gly Val Ile Ala Asn Gln Asp Pro Ile Ala Val  *
GGT GTA ATC GCT AAC CAA GAC CCT ATC GCT GTC TAA AAC CGA AAT ACA          670
 || ||| ||  ||| ||| ||| ||| ||| ||  ||| ||  ||| ||| |  ||| | |
AGT GTA ATT GCT AAC CAA GAC CCT ATT GCT GTA TAA AAC CTA AAT AAA
S
```

```
CCC ATA GAT TCA CCT GTA AAA CTT TAT TTT ATA TAA TAA AGT ATT CCA          718
|  | ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
CAC ATA GAT TCA CCT GTA AAA CTT TAT TTT ATA TAA TAA AGT ATT CCA
```

```
CCT TAA ATT AAA CAA                                                      733
||| ||| ||| ||| |||
CCT TAA ATT AAA CAA
```

11/18

FIG. 15
SEGMENT F: (SEQ ID NOS:45-48)

```
AGTTTCCCCC CCCAACTTGT CGGAACTCTG GGCTCGCGCG CAGGGCAGGA GCGGAGCGGC          60

GGCGGCTGCC CAGGCGATGC GAGCGCGGGC CGGACGGTAA TCGCCTCTCC CTCCTCGGGC         120

TGCGAGCGCG CCGGACCGAG GCAGCGACAG GAGCGGACCG CGGCGGGAAC CGAGGACTCC         180

CCAGCGGCGC GCCAGCAGGA GCCACCCCGC GAGNCGTGCG ACCGGGACGG AGCGCCCGCC         240

AGTCCCAGGT GGCCCGGACC GCACGTTGCG TCCCCGCGCT CCCCGCCGGC GACAGGAGAC         300

GCTCCCCCCC ACGCCGCGCG CGCCTCGGCC CGGTCGCTGG CCCGCCTCCA CTCCGGGGAC         360
          ||||| | ||||||| || ||| ||||| | |||| || ||| |||||
          CGCGAG CGCCTCAGCG CGGCCGCTCG CTCTC..CCC CTCGAGGGAC

AAACTTTTCC CGAAGCCGAT CCCAGCCCTC GGACCCAAAC TTGTCGCGCG TCGCCTTCGC         420
|||||||||| | ||| ||||| || |||||| |||||| |              |||||| |||
AAACTTTTCC CAAACCCGAT CCGAGCCCTT GGACCAAA.. .........C TCGCCTGCGC

                                         Met Ser Glu Arg Arg
CGGGAGCCGT CCGCGCAGAG CGTGCACTTC TCGGGCGAG ATG TCG GAG CGC AGA         474
|| ||||||| ||||| |||| || | | || |||||||| ||| || ||| ||| |
CGAGAGCCGT CCGCGTAGAG CGCTC.CGTC TCCGGCGAG ATG TCC GAG CGC AAA
                                                          K

Glu Gly Lys Gly Lys Gly Lys Gly Gly Lys Lys Asp Arg Gly Ser Gly
GAA GGC AAA GGC AAG GGG AAG GGC GGC AAG AAG GAC CGA GGC TCC GGG         522
||| ||| | | ||| || ||| ||| ||| ||| ||| || ||| ||| ||| ||
GAA GGC AGA GGC AAA GGG AAG GGC AAG AAG AAG GAG CGA GGC TCC GGC
        R                       K           E

Lys Lys Pro Val Pro Ala Ala Gly Gly Pro Ser Pro Ala
AAG AAG CCC GTG CCC GCG GCT GGC GGC CCG AGC CCA G                       559
||| ||| || | | || ||| || ||| || | | ||| ||| |
AAG AAG CCG GAG TCC GCG GCG GGC AGC CAG AGC CCA G
        E   S
```

FIG. 16A
(SEQ ID NOS:49-50)

```
G AAG TCA GAA CTT CGC ATT AGC AAA GCG TCA CTG GCT GAT TCT GGA GAA          49
  Lys Ser Glu Leu Arg Ile Ser Lys Ala Ser Leu Ala Asp Ser Gly Glu
   1               5                  10                  15

TAT ATG TGC AAA GTG ATC AGC AAA CTA GGA AAT GAC AGT GCC TCT GCC          97
Tyr Met Cys Lys Val Ile Ser Lys Leu Gly Asn Asp Ser Ala Ser Ala
              20                  25                  30

AAC ATC ACC ATT GTG GAG TCA AAC GCC ACA TCC ACA TCT ACA GCT GGG          145
Asn Ile Thr Ile Val Glu Ser Asn Ala Thr Ser Thr Ser Thr Ala Gly
          35                  40                  45

ACA AGC CAT CTT GTC AAG TGT GCA GAG AAG GAG AAA ACT TTC TGT GTG          193
Thr Ser His Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val
          50                  55                  60

AAT GGA GGC GAC TGC TTC ATG GTG AAA GAC CTT TCA AAT CCC TCA AGA          241
Asn Gly Gly Asp Cys Phe Met Val Lys Asp Leu Ser Asn Pro Ser Arg
65                  70                  75                  80

TAC TTG TGC AAG TGC CAA CCT GGA TTC ACT GGA GCG AGA TGT ACT GAG          289
Tyr Leu Cys Lys Cys Gln Pro Gly Phe Thr Gly Ala Arg Cys Thr Glu
              85                  90                  95

AAT GTG CCC ATG AAA GTC CAA ACC CAA GAA AAA GCG GAG GAG CTC TAC          337
Asn Val Pro Met Lys Val Gln Thr Gln Glu Lys Ala Glu Glu Leu Tyr
              100                 105                 110

CAG AAG AGA GTG CTC ACC ATT ACC GGC ATT TGC ATC GCG CTG CTC GTG          385
Gln Lys Arg Val Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu Val
          115                 120                 125

GTT GGC ATC ATG TGT GTG GTG GTC TAC TGC AAA ACC AAG AAA CAA CGG          433
Val Gly Ile Met Cys Val Val Val Tyr Cys Lys Thr Lys Lys Gln Arg
          130                 135                 140

AAA AAG CTT CAT GAC CGG CTT CGG CAG AGC CTT CGG TCT GAA AGA AAC          481
Lys Lys Leu His Asp Arg Leu Arg Gln Ser Leu Arg Ser Glu Arg Asn
145                 150                 155                 160

ACC ATG ATG AAC GTA GCC AAC GGG CCC CAC CAC CCC AAT CCG CCC CCC          529
Thr Met Met Asn Val Ala Asn Gly Pro His His Pro Asn Pro Pro Pro
              165                 170                 175

GAG AAC GTG CAG CTG GTG AAT CAA TAC GTA TCT AAA AAT GTC ATC TCT          577
Glu Asn Val Gln Leu Val Asn Gln Tyr Val Ser Lys Asn Val Ile Ser
              180                 185                 190
```

FIG. 16B

```
AGC GAG CAT ATT GTT GAG AGA GAG GCG GAG AGC TCT TTT TCC ACC AGT        625
Ser Glu His Ile Val Glu Arg Glu Ala Glu Ser Ser Phe Ser Thr Ser
        195                 200                 205

CAC TAC ACT TCG ACA GCT CAT CAT TCC ACT ACT GTC ACT CAG ACT CCC        673
His Tyr Thr Ser Thr Ala His His Ser Thr Thr Val Thr Gln Thr Pro
        210                 215                 220

AGT CAC AGC TGG AGC AAT GGA CAC ACT GAA AGC ATC ATT TCG GAA AGC        721
Ser His Ser Trp Ser Asn Gly His Thr Glu Ser Ile Ile Ser Glu Ser
225                 230                 235                 240

CAC TCT GTC ATC GTG ATG TCA TCC GTA GAA AAC AGT AGG CAC AGC AGC        769
His Ser Val Ile Val Met Ser Ser Val Glu Asn Ser Arg His Ser Ser
                245                 250                 255

CCG ACT GGG GGC CCG AGA GGA CGT CTC AAT GGC TTG GGA GGC CCT CGT        817
Pro Thr Gly Gly Pro Arg Gly Arg Leu Asn Gly Leu Gly Gly Pro Arg
            260                 265                 270

GAA TGT AAC AGC TTC CTC AGG CAT GCC AGA GAA ACC CCT GAC TCC TAC        865
Glu Cys Asn Ser Phe Leu Arg His Ala Arg Glu Thr Pro Asp Ser Tyr
            275                 280                 285

CGA GAC TCT CCT CAT AGT GAA AGA CAT AAC CTT ATA GCT GAG CTA AGG        913
Arg Asp Ser Pro His Ser Glu Arg His Asn Leu Ile Ala Glu Leu Arg
        290                 295                 300

AGA AAC AAG GCC CAC AGA TCC AAA TGC ATG CAG ATC CAG CTT TCC GCA        961
Arg Asn Lys Ala His Arg Ser Lys Cys Met Gln Ile Gln Leu Ser Ala
305                 310                 315                 320

ACT CAT CTT AGA GCT TCT TCC ATT CCC CAT TGG GCT TCA TTC TCT AAG       1009
Thr His Leu Arg Ala Ser Ser Ile Pro His Trp Ala Ser Phe Ser Lys
                325                 330                 335

ACC CCT TGG CCT TTA GGA AGG TAT GTA TCA GCA ATG ACC ACC CCG GCT       1057
Thr Pro Trp Pro Leu Gly Arg Tyr Val Ser Ala Met Thr Thr Pro Ala
                340                 345                 350

CGT ATG TCA CCT GTA GAT TTC CAC ACG CCA AGC TCC CCC AAG TCA CCC       1105
Arg Met Ser Pro Val Asp Phe His Thr Pro Ser Ser Pro Lys Ser Pro
        355                 360                 365

CCT TCG GAA ATG TCC CCG CCC GTG TCC AGC ACG ACG GTC TCC ATG CCC       1153
Pro Ser Glu Met Ser Pro Pro Val Ser Ser Thr Thr Val Ser Met Pro
        370                 375                 380
```

FIG. 16C

```
TCC ATG GCG GTC AGT CCC TTC GTG GAA GAG GAG AGA CCC CTG CTC CTT    1201
Ser Met Ala Val Ser Pro Phe Val Glu Glu Glu Arg Pro Leu Leu Leu
385             390             395             400

GTG ACG CCA CCA CGG CTG CGG GAG AAG TAT GAC CAC CAC GCC CAG CAA    1249
Val Thr Pro Pro Arg Leu Arg Glu Lys Tyr Asp His His Ala Gln Gln
            405             410             415

TTC AAC TCG TTC CAC TGC AAC CCC GCG CAT GAG AGC AAC AGC CTG CCC    1297
Phe Asn Ser Phe His Cys Asn Pro Ala His Glu Ser Asn Ser Leu Pro
            420             425             430

CCC AGC CCC TTG AGG ATA GTG GAG GAT GAG GAA TAT GAA ACG ACC CAG    1345
Pro Ser Pro Leu Arg Ile Val Glu Asp Glu Glu Tyr Glu Thr Thr Gln
            435             440             445

GAG TAC GAA CCA GCT CAA GAG CCG GTT AAG AAA CTC ACC AAC AGC AGC    1393
Glu Tyr Glu Pro Ala Gln Glu Pro Val Lys Lys Leu Thr Asn Ser Ser
    450             455             460

CGG CGG GCC AAA AGA ACC AAG CCC AAT GGT CAC ATT GCC CAC AGG TTG    1441
Arg Arg Ala Lys Arg Thr Lys Pro Asn Gly His Ile Ala His Arg Leu
465             470             475             480

GAA ATG GAC AAC AAC ACA GGC GCT GAC AGC AGT AAC TCA GAG AGC GAA    1489
Glu Met Asp Asn Asn Thr Gly Ala Asp Ser Ser Asn Ser Glu Ser Glu
            485             490             495

ACA GAG GAT GAA AGA GTA GGA GAA GAT ACG CCT TTC CTG GCC ATA CAG    1537
Thr Glu Asp Glu Arg Val Gly Glu Asp Thr Pro Phe Leu Ala Ile Gln
            500             505             510

AAC CCC CTG GCA GCC AGT CTC GAG GCG GCC CCT GCC TTC CGC CTG GTC    1585
Asn Pro Leu Ala Ala Ser Leu Glu Ala Ala Pro Ala Phe Arg Leu Val
            515             520             525

GAC AGC AGG ACT AAC CCA ACA GGC GGC TTC TCT CCG CAG GAA GAA TTG    1633
Asp Ser Arg Thr Asn Pro Thr Gly Gly Phe Ser Pro Gln Glu Glu Leu
            530             535             540

CAG GCC AGG CTC TCC GGT GTA ATC GCT AAC CAA GAC CCT ATC GCT GTC    1681
Gln Ala Arg Leu Ser Gly Val Ile Ala Asn Gln Asp Pro Ile Ala Val
545             550             555             560

TAAAACCGAA ATACACCCAT AGATTCACCT GTAAAACTTT ATTTTATATA ATAAAGTATT    1741

CCACCTTAAA TTAAACAAAA AAA                                           1764
```

15/18

FIG. 17A
(SEQ ID NOS:51-52)

```
CAT CAA GTG TGG GCG GCG AAA GCC GGG GGC TTG AAG AAG GAC TCG CTG        48
His Gln Val Trp Ala Ala Lys Ala Gly Gly Leu Lys Lys Asp Ser Leu
1                5                  10                  15

CTC ACC GTG CGC CTG GGC GCC TGG GGC CAC CCC GCC TTC CCC TCC TGC        96
Leu Thr Val Arg Leu Gly Ala Trp Gly His Pro Ala Phe Pro Ser Cys
                20                  25 .                30

GGG CGC CTC AAG GAG GAC AGC AGG TAC ATC TTC TTC ATG GAG CCC GAG       144
Gly Arg Leu Lys Glu Asp Ser Arg Tyr Ile Phe Phe Met Glu Pro Glu
            35                  40                  45

GCC AAC AGC AGC GGC GGG CCC GGC CGC CTT CCG AGC CTC CTT CCC CCC       192
Ala Asn Ser Ser Gly Gly Pro Gly Arg Leu Pro Ser Leu Leu Pro Pro
        50                  55                  60

TCT CGA GAC GGG CCG GAA CCT CAA GAA GGA GGT CAG CCG GGT GCT GTG       240
Ser Arg Asp Gly Pro Glu Pro Gln Glu Gly Gly Gln Pro Gly Ala Val
65                  70                  75                  80

CAA CGG TGC GCC TTG CCT CCC CGC TTG AAA GAG ATG AAG AGT CAG GAG       288
Gln Arg Cys Ala Leu Pro Pro Arg Leu Lys Glu Met Lys Ser Gln Glu
                85                  90                  95

TCT GTG GCA GGT TCC AAA CTA GTG CTT CGG TGC GAG ACC AGT TCT GAA       336
Ser Val Ala Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser Ser Glu
                100                 105                 110

TAC TCC TCT CTC AAG TTC AAG TGG TTC AAG AAT GGG AGT GAA TTA AGC       384
Tyr Ser Ser Leu Lys Phe Lys Trp Phe Lys Asn Gly Ser Glu Leu Ser
            115                 120                 125

CGA AAG AAC AAA CCA GAA AAC ATC AAG ATA CAG AAA AGG CCG GGG AAG       432
Arg Lys Asn Lys Pro Glu Asn Ile Lys Ile Gln Lys Arg Pro Gly Lys
        130                 135                 140

TCA GAA CTT CGC ATT AGC AAA GCG TCA CTG GCT GAT TCT GGA GAA TAT       480
Ser Glu Leu Arg Ile Ser Lys Ala Ser Leu Ala Asp Ser Gly Glu Tyr
145                 150                 155                 160

ATG TGC AAA GTG ATC AGC AAA CTA GGA AAT GAC AGT GCC TCT GCC AAC       528
Met Cys Lys Val Ile Ser Lys Leu Gly Asn Asp Ser Ala Ser Ala Asn
                165                 170                 175
```

FIG. 17B

```
ATC ACC ATT GTG GAG TCA AAC GCC ACA TCC ACA TCT ACA GCT GGG ACA          576
Ile Thr Ile Val Glu Ser Asn Ala Thr Ser Thr Ser Thr Ala Gly Thr
            180                 185                 190

AGC CAT CTT GTC AAG TGT GCA GAG AAG GAG AAA ACT TTC TGT GTG AAT          624
Ser His Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn
            195                 200                 205

GGA GGC GAG TGC TTC ATG GTG AAA GAC CTT TCA AAT CCC TCA AGA TAC          672
Gly Gly Glu Cys Phe Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr
            210                 215                 220

TTG TGC AAG TGC CAA CCT GGA TTC ACT GGA GCG AGA TGT ACT GAG AAT          720
Leu Cys Lys Cys Gln Pro Gly Phe Thr Gly Ala Arg Cys Thr Glu Asn
225                 230                 235                 240

GTG CCC ATG AAA GTC CAA ACC CAA GAA AAG TGC CCA AAT GAG TTT ACT          768
Val Pro Met Lys Val Gln Thr Gln Glu Lys Cys Pro Asn Glu Phe Thr
                245                 250                 255

GGT GAT CGC TGC CAA AAC TAC GTA ATG GCC AGC TTC TAC AGT ACG TCC          816
Gly Asp Arg Cys Gln Asn Tyr Val Met Ala Ser Phe Tyr Ser Thr Ser
                260                 265                 270

ACT CCC TTT CTG TCT CTG CCT GAA TAGCGCATCT CAGTCGGTGC CGCTTTCTTG          870
Thr Pro Phe Leu Ser Leu Pro Glu
            275                 280

TTGCCGCATC TCCCCTCAGA TTCCNCCTAG AGCTAGATGC GTTTTACCAG GTCTAACATT          930

GACTGCCTCT GCCTGTCGCA TGAGAACATT AACACAAGCG ATTGTATGAC TTCCTCTGTC          990

CGTGACTAGT GGGCTCTGAG CTACTCGTAG GTGCGTAAGG CTCCAGTGTT TCTGAAATTG         1050

ATCTTGAATT ACTGTGATAC GACATGATAG TCCCTCTCAC CCAGTGCAAT GACAATAAAG         1110

GCCTTGAAAA GTCAAAAAAA AAAAAAAAAA                                         1140
```

FIG. 18A
(SEQ ID NOS:53-54)

```
AGTTTCCCCC CCCAACTTGT CGGAACTCTG GGCTCGCGCG CAGGGCAGGA GCGGAGCGGC      60

GGCGGCTGCC CAGGCGATGC GAGCGCGGGC CGGACGGTAA TCGCCTCTCC CTCCTCGGGC     120

TGCGAGCGCG CCGGACCGAG GCAGCGACAG GAGCGGACCG CGGCGGGAAC CGAGGACTCC     180

CCAGCGGCGC GCCAGCAGGA GCCACCCCGC GAGCGTGCGA CCGGGACGGA GCGCCCGCCA     240

GTCCCAGGTG GCCCGGACCG CACGTTGCGT CCCCGCGCTC CCCGCCGGCG ACAGGAGACG     300

CTCCCCCCCA CGCCGCGCGC GCCTCGGCCC GGTCGCTGGC CCGCCTCCAC TCCGGGGACA     360

AACTTTTCCC GAAGCCGATC CCAGCCCTCG GACCCAAACT TGTCGCGCGT CGCCTTCGCC     420
```

```
GGGAGCCGTC CGCGCAGAGC GTGCACTTCT CGGGCGAG ATG TCG GAG CGC AGA         473
                                          Met Ser Glu Arg Arg
                                          1                    5

GAA GGC AAA GGC AAG GGG AAG GGC GGC AAG AAG GAC CGA GGC TCC GGG      521
Glu Gly Lys Gly Lys Gly Lys Gly Gly Lys Lys Asp Arg Gly Ser Gly
              10                    15                   20

AAG AAG CCC GTG CCC GCG GCT GGC GGC CCG AGC CCA GCC TTG CCT CCC      569
Lys Lys Pro Val Pro Ala Ala Gly Gly Pro Ser Pro Ala Leu Pro Pro
              25                    30                   35

CGC TTG AAA GAG ATG AAG ATG CAG GAG TCT GTG GCA GGT TCC AAA CTA      617
Arg Leu Lys Glu Met Lys Met Gln Glu Ser Val Ala Gly Ser Lys Leu
              40                    45                   50

GTG CTT CGG TGC GAG ACC AGT TCT GAA TAC TCC TCT CTC AAG TTC AAG      665
Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser Ser Leu Lys Phe Lys
              55                    60                   65

TGG TTC AAG AAT GGG AGT GAA TTA AGC CGA AAG AAC AAA CCA CAA AAC      713
Trp Phe Lys Asn Gly Ser Glu Leu Ser Arg Lys Asn Lys Pro Gln Asn
70                  75                   80                   85

ATC AAG ATA CAG AAA AGG CCG GGG AAG TCA GAA CTT CGC ATT AGC AAA      761
Ile Lys Ile Gln Lys Arg Pro Gly Lys Ser Glu Leu Arg Ile Ser Lys
                    90                   95                   100

GCG TCA CTG GCT GAT TCT GGA GAA TAT ATG TGC AAA GTG ATC AGC AAA      809
Ala Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys Lys Val Ile Ser Lys
                    105                  110                  115
```

FIG. 18B

```
CTA GGA AAT GAC AGT GCC TCT GCC AAC ATC ACC ATT GTG GAG TCA AAC        857
Leu Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr Ile Val Glu Ser Asn
        120             125             130

GAG ATC ACC ACT GGC ATG CCA GCC TCA ACT GAG ACA GCG TAT GTG TCT        905
Glu Ile Thr Thr Gly Met Pro Ala Ser Thr Glu Thr Ala Tyr Val Ser
        135             140             145

TCA GAG TCT CCC ATT AGA ATA TCA GTA TCA ACA GAA GGA ACA AAT ACT        953
Ser Glu Ser Pro Ile Arg Ile Ser Val Ser Thr Glu Gly Thr Asn Thr
150             155             160             165

TCT TCA TCC ACA TCC ACA TCT ACA GCT GGG ACA AGC CAT CTT GTC AAG       1001
Ser Ser Ser Thr Ser Thr Ser Thr Ala Gly Thr Ser His Leu Val Lys
                170             175             180

TGT GCA GAG AAG GAG AAA ACT TTC TGT GTG AAT GGA GGC GAG TGC TTC       1049
Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys Phe
                185             190             195

ATG GTG AAA GAC CTT TCA AAT CCC TCA AGA TAC TTG TGC AAG TGC CCA       1097
Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys Lys Cys Pro
                200             205             210

AAT GAG TTT ACT GGT GAT CGC TGC CAA AAC TAC GTA ATG GCC AGC TTC       1145
Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val Met Ala Ser Phe
                215             220             225

TAC AGT ACG TCC ACT CCC TTT CTG TCT CTG CCT GAA TAGGCGCATG           1191
Tyr Ser Thr Ser Thr Pro Phe Leu Ser Leu Pro Glu
230             235             240

CTCAGTCGGT GCCGCTTTCT TGTTGCCGCA TCTCCCCTCA GATTCAACCT AGAGCTAGAT    1251

GCGTTTTACC AGGTCTAACA TTGACTGCCT CTGCCTGTCG CATGAGAACA TTAACACAAG    1311

CGATTGTATG ACTTCCTCTG TCCGTGACTA GTGGGCTCTG AGCTACTCGT AGGTGCGTAA    1371

GGCTCCAGTG TTTCTGAAAT TGATCTTGAA TTACTGTGAT ACGACATGAT AGTCCCTCTC    1431

ACCCAGTGCA ATGACAATAA AGGCCTTGAA AAGTCTCACT TTTATTGAGA AAATAAAAAT    1491

CGTTCCACGG GACAGTCCCT CTTCTTTATA AAATGACCCT ATCCTTGAAA AGGAGGTGTG    1551

TTAAGTTGTA ACCAGTACAC ACTTGAAATG ATGGTAAGTT CGCTTCGGTT CAGAATGTGT    1611

TCTTTCTGAC AAATAAACAG AATAAAAAAA AAAAAAAAAA A                       1652
```

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled THERAPEUTIC METHODS COMPRISING USE OF A NEUREGULIN, the specification of which

      ☐ is attached hereto.
      ☒ was filed on May 5, 2000 as Application Serial No. 09/530,884
      and was amended on _____.
      ☒ was described and claimed in PCT International Application No. PCT/US98/21349
      filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

FOREIGN PRIORITY RIGHTS: I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Serial Number	Filing Date	Priority Claimed?
PCT	PCT/US98/21349	08 October 1998	Yes

PROVISIONAL PRIORITY RIGHTS: I hereby claim priority benefits under Title 35, United States Code, §119(e) and §120 of any United States provisional patent application(s) listed below filed by an inventor or inventors on the same subject matter as the present application and having a filing date before that of the application(s) of which priority is claimed:

Serial Number	Filing Date	Status
60/062,109	14 October 1997	Abandoned

NON-PROVISIONAL PRIORITY RIGHTS: I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by

COMBINED DECLARATION AND POWER OF ATTORNEY

the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Serial Number	Filing Date	Status

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Paul T. Clark, Reg. No. 30,162, Karen L. Elbing, Ph.D. Reg. No. 35,238, Kristina Bieker-Brady, Ph.D. Reg. No. 39,109, Susan M. Michaud, Ph.D. Reg. No. 42,885, Mary Rose Scozzafava, Ph.D., Reg. No.36,268, James D. DeCamp, Ph.D., Reg. No. 43,580.

Address all telephone calls to: Kristina Bieker-Brady, Ph.D. at 617/428-0200.

Address all correspondence to: Kristina Bieker-Brady, Ph.D. at Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Robert N. McBurney	Newton, MA	20 Leslie Road Newton, MA 02166	United States
Signature: *Robert N. McBurney*			Date: 7/5/00

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
William Holt	Natick, MA	162 A East Central Street Natick, MA 01760	United States
Signature: *William F. Holt*			Date: 7/21/00

COMBINED DECLARATION AND POWER OF ATTORNEY

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
David I. Gwynne	Beverly, MA	77 Grover Street Beverly, MA _MA_	United States
Signature: _[signature]_			Date: _6/24/00_

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Mark Marchionni	Arlington, MA	24 Twin Circle Drive Arlington, MA 02174	United States
Signature: _[signature]_ _MA_			Date: _2/5/00_